Nucleic acid lipid nanoparticle with low no-load rate and preparation method therefor

By improving the fusion degree of lipid nanoparticles and buffer replacement process, the problems of LNP instability and high no-load rate are solved, the stability and efficient delivery of nucleic acid drugs under mild conditions are achieved, and the risk of inflammatory reactions is reduced .

WO2024245341A1PCT designated stage expired Publication Date: 2024-12-05CSPC ZHONGQI PHARMACEUTICAL TECHNOLOGY (SHIJIAZHUANG) CO LTD
View PDF 4 Cites 0 Cited by

Patent Information

Application Number
PCT/CN2024/096347
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-11-10
Filing Date
2024-05-30
Publication Date
2024-12-05

AI Technical Summary

Technical Problem

In the existing nucleic acid drug delivery technology, the instability and high no-load rate of lipid nanoparticles (LNPs) lead to difficulties in storage and transportation, affecting the safety and effectiveness of drugs. In particular, mRNA vaccines require low temperature storage and may cause inflammation. Adverse reactions.

Method used

By increasing the degree of fusion of lipid nanoparticles and reducing the no-load rate, a two-stage buffer replacement process is used to form thermodynamically stable finished lipid nanoparticles, ensuring high nucleic acid encapsulation rate and low no-load rate, improving drug stability and safety sex.

Benefits of technology

The stability of nucleic acid drugs stored under mild conditions is achieved, the risk of inflammatory adverse reactions is reduced, the delivery efficiency and safety of drugs is improved, and the storage and transportation process is simplified.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN2024096347_05122024_PF_FP_ABST
    Figure CN2024096347_05122024_PF_FP_ABST
Patent Text Reader

Abstract

A lipid nanoparticle composition for encapsulating a nucleic acid and a preparation method therefor. In the composition, the proportion of empty lipid nanoparticles containing no nucleic acid to the total number of lipid nanoparticles, i.e., the no-load rate is no more than 10%. According to the preparation method, the ethanol content in the system is reduced to an acceptable level during particle fusion, so that the particles are fully fused.
Need to check novelty before this filing date? Find Prior Art

Description

A kind of nucleic acid lipid nanoparticles with low empty loading rate and preparation method thereof

[0001] CROSS-REFERENCE TO RELATED APPLICATIONS

[0002] This application claims priority to Chinese Patent Application No. 202310626158.9 filed on May 30, 2023 and Chinese Patent Application No. 202311497985.9 filed on November 10, 2023, the entire contents of the above two patent applications are hereby incorporated herein by reference Technical Field

[0003] The present application belongs to the field of biomedicine technology. Specifically, the present application relates to a low-empty-rate lipid nanoparticle containing nucleic acid and a preparation method thereof. Background Art

[0004] Half a century ago, Friedmann and Roblin proposed that dysfunction caused by genetic diseases could be treated by introducing functional genes. Conventional drug targets are usually proteins, while nucleic acid drugs produce therapeutic effects by regulating gene expression. This method of introducing exogenous nucleic acids into cells to eliminate defective genes is a very effective treatment method, which can achieve highly specific and long-lasting therapeutic effects. In the past 30 years, nucleic acid drugs have also made breakthrough research progress. Several in vitro and in vivo nucleic acid drugs for the prevention or treatment of genetic diseases such as infection, cancer, muscle and retinal dystrophy have been approved or are in late clinical development.

[0005] Nucleic acid molecules are relatively unstable and easily degraded by nucleases in the body. Furthermore, because they carry a large negative charge, they cannot penetrate the cell membrane and enter the cytoplasm to exert their therapeutic effects. Therefore, nucleic acid drugs require specific delivery technologies to be delivered intracellularly in order to be effective. Currently, commonly used nucleic acid delivery technologies include lipid nanoparticles (LNPs), electroporation, protamine, cationic nanoemulsions, cationic lipid complexes, lipid-polymer complexes, polymer nanoparticles, and inorganic nanoparticles. Electroporation uses high-voltage pulses to create pores in the cell membrane, allowing nucleic acids to be delivered directly into human cells. Other methods mostly protect nucleic acids from degradation or promote fusion between nucleic acids and cell membranes to improve delivery efficiency. For example, protamine is a naturally occurring cationic protein that can complex negatively charged nucleic acids into nanoparticles, thereby protecting them from degradation by nucleases in the serum. However, because protamine binds tightly to nucleic acids, the efficiency of intracellular protein expression of nucleic acid drugs using this technology is affected.

[0006] Nucleic acid drugs, especially mRNA vaccines, played an important role in epidemic prevention during the outbreak and widespread spread of the new coronavirus and received widespread attention. Both use LNPs for delivery. LNPs are the most advanced non-viral gene delivery system in clinical practice. Compared to other types of nucleic acid drug delivery systems, LNPs offer many advantages, such as high nucleic acid encapsulation efficiency and effective cell transfection, strong tissue penetration, and low cytotoxicity and immunogenicity. These advantages make LNPs an excellent nucleic acid delivery system.

[0007] LNP is usually formed by self-assembly through rapid mixing of lipids in the organic phase and nucleic acids in the aqueous phase, followed by removal of the organic solvent and completion of buffer replacement by dialysis or ultrafiltration. The typical preparation process and particle formation mechanism of LNP are as follows: (1) Mixing process: The lipids are dissolved in the organic solvent and the nucleic acids are dissolved in the acidic (e.g. pH 4.0) buffer. When the two phases are mixed, since the pH value of the system is significantly lower than the pKa of the ionizable lipids, the ionizable cationic lipids are protonated and positively charged, and electrostatic attraction occurs between them and the negatively charged nucleic acids. At the same time, due to the poor water solubility of the lipids, hydrophobic interactions are generated, driving the lipid-encapsulated nucleic acids to self-assemble into lipid nanoparticles. Cryogenic transmission electron microscopy (Cryo-TEM) shows that under this condition, There are at least two forms of LNPs: vesicular particles containing a double-layer structure and electron-dense structure particles; (2) Dialysis or ultrafiltration process: During the dialysis or ultrafiltration process, as the mixed solution is replaced by a buffer solution with a physiological pH value (e.g., pH 7.4), the ionizable cationic lipids are deprotonated, lose most of their positive charge, and the electrostatic repulsion between particles decreases; the ionizable cationic lipids migrate inward to form a hydrophobic amorphous core, the double-layer structure of the particles is destroyed, and the particles fuse to compensate for the decrease in the ratio of surface lipids to core lipids. After fusion, the size of the LNP increases (Kulkarni JA, et al. On the Formation and Morphology of Lipid Nanoparticles Containing Ionizable Cationic Lipids and siRNA. ACS Nano. 2018 May 22; 12(5): 4787-4795). Different literatures have reported different morphologies of LNPs after dialysis, such as spherical electron-dense structures or non-spherical electron-dense structures containing vesicles of different size ratios, indicating that the physicochemical properties of the finished LNPs after fusion are different due to the influence of formulation and process factors. Changes in the physicochemical properties (composition and structure) of LNPs have been shown to affect their stability and safety.

[0008] The instability of LNPs and their need for ultra-low temperature storage restrict the storage, transportation, and distribution of nucleic acid therapeutics, particularly mRNA vaccines, thereby impacting their cost and accessibility. Two marketed novel coronavirus mRNA vaccines, BNT162b2 and mRNA-1273, require storage at -80°C to -60°C and -25°C to -15°C, respectively, and have a shelf life of only six months. Long-term storage of LNPs can lead to particle aggregation and sedimentation, oxidative hydrolysis of mRNA, and irreversible changes in phase after freeze-thaw. Neutron scattering was used to characterize the thermal stability of the Pfizer-BioNtech novel coronavirus mRNA vaccine. The changes in the molecular vibration spectrum during the freeze-thaw process showed that the vaccine exhibited a two-step melting process when first heated from a low-temperature frozen state, indicating that it was in a two-phase morphology; when it was frozen again and heated, it exhibited a one-step melting process, indicating that it was in a single-phase morphology. That is, after one freeze-thaw cycle, the two-phase morphology of the Pfizer-BioNtech novel coronavirus mRNA vaccine underwent irreversible changes, forming a single-phase morphology with greatly increased molecular-level fluidity and softness, thereby having an irreversible adverse effect on the long-term storage stability of the vaccine (Mamontov E, et al. Melting and Re-Freezing Leads to Irreversible Changes in the Morphology and Molecular-Level Dynamics of Pfizer-BioNTech COVID-19 Vaccine. Medicina (Kaunas). 2021 Dec 9; 57(12): 1343).

[0009] With the widespread vaccination of COVID-19 mRNA vaccines during this pandemic, the safety of nucleic acid drugs has also received widespread attention. A large-scale study of tens of millions of people quantified for the first time the risk of adverse cardiac events (myocarditis, pericarditis, and arrhythmia) associated with COVID-19 vaccination. The study showed that vaccination with mRNA and adenovirus vaccines in adults was associated with an increased risk of myocarditis; in men under 40 years old, the number of excessive myocarditis events per million people after the second dose of the mRNA vaccine mRNA-1273 was higher than after SARS-CoV-2 infection, and significantly higher than the mRNA vaccine BNT162b2 and adenovirus vaccine ChAdOx1. The difference in the incidence of cardiac-related adverse events between different mRNA vaccines may be related to the differences in in vivo behavior caused by the composition and structure of mRNA LNPs (Patone M, et al. Risk of Myocarditis After Sequential Doses of COVID-19 Vaccine and SARS-CoV-2 Infection by Age and Sex. Circulation. 2022 Sep 6; 146(10): 743-754).

[0010] Compared with traditional technology vaccines such as inactivated vaccines and subunit vaccines, mRNA vaccines can promote very strong humoral and cellular immune responses. Studies have shown that empty LNPs without nucleic acids can stimulate specific pathways of the immune system and achieve specific activation of the immune system. This is the advantage of LNP as a vaccine delivery carrier; however, at the same time, the inflammatory nature of LNPs can also cause typical inflammatory side effects such as pain, swelling, and fever. With the development of vaccine-related technologies, it is necessary to seek a balance between the advantages of LNP immune responses and adverse inflammatory reactions (Ndeupen S, et al. The mRNA-LNP platform's lipid nanoparticle component used in preclinical vaccine studies is highly inflammatory. iScience. 2021 Dec 17; 24(12): 103479). The empty loading rate of LNPs is a key characteristic of nucleic acid delivery vectors. Studies have shown that LNPs prepared using traditional methods may contain 40%-80% empty particles (Li S, et al. Payload distribution and capacity of mRNA lipidnanoparticles. Nat Commun. 2022 Sep 23; 13(1): 5561). Empty LNPs cannot deliver nucleic acids into cells and instead increase the risk of inflammatory adverse reactions, affecting the safety of nucleic acid drugs.

[0011] In summary, it remains desirable to provide lipid nanoparticles for delivering therapeutic or prophylactic nucleic acid drugs with improved safety, stability and efficacy.

[0012] Summary of the Invention

[0013] An object of the present invention is to provide a lipid nanoparticle composition with low empty loading rate for delivering therapeutic or prophylactic nucleic acid drugs.

[0014] Another object of the present invention is to provide a method for preparing a lipid nanoparticle composition with low empty loading rate for delivering therapeutic or prophylactic nucleic acid drugs.

[0015] A technical problem to be solved by the present invention is to provide a lipid nanoparticle composition for encapsulating nucleic acids with a low empty load rate.

[0016] Another technical problem to be solved by the present invention is to provide a lipid nanoparticle composition for encapsulating nucleic acids with low empty rate and improved thermal stability.

[0017] Another technical problem to be solved by the present invention is to provide a lipid nanoparticle composition for encapsulating nucleic acids with low empty rate, improved thermal stability and improved safety.

[0018] Another technical problem to be solved by the present invention is to provide a method for preparing the nucleic acid-lipid nanoparticle composition having one or more of the above advantages.

[0019] In order to solve the above technical problems, the inventors of this application studied the preparation process of nucleic acid lipid nanoparticles and found that by increasing the degree of fusion of particles, nucleic acid lipid nanoparticles with a low empty load rate can be obtained. The obtained nucleic acid lipid nanoparticles have improved safety, stability and effectiveness, thereby meeting the needs of the existing technology.

[0020] In a first aspect of the present invention, a lipid nanoparticle composition for encapsulating nucleic acids is provided, characterized in that the lipid nanoparticles have an empty loading ratio of no greater than 10%, wherein the empty loading ratio refers to the ratio of empty lipid nanoparticles that do not contain nucleic acids to the total number of lipid nanoparticles in the composition. In some embodiments, the empty loading ratio of the lipid nanoparticles is no greater than 9%, preferably no greater than 8.5%, more preferably no greater than 6%, and even more preferably no greater than 3%, or any value within the foregoing range, for example, 2%, 3%, 4%, 5%, 6%, 7%, 7.1%, 7.6%, 7.7%, 7.9%, 8%, 8.3%, or 9%.

[0021] In some embodiments, the average particle size of the lipid nanoparticles is 50 nm to 150 nm, preferably 70 nm to 120 nm, more preferably 90 nm to 110 nm, or any value within the above range, for example, 96 nm, 97 nm, 98 nm, 99 nm, 100 nm, 101 nm, 102 nm, 103 nm, 104 nm, 105 nm, 106 nm, 107 nm, 108 nm, 109 nm, 110 nm, 111 nm, 112 nm, 113 nm, 114 nm, 115 nm, 116 nm, 117 nm, 118 nm, 119 nm or 120 nm.

[0022] In some embodiments, the encapsulation efficiency of the lipid nanoparticles is greater than 80%, preferably greater than 85%, and more preferably greater than 90%.

[0023] In some embodiments, the nucleic acid-encapsulated lipid nanoparticle composition is provided, wherein the lipid nanoparticle comprises:

[0024] (1) nucleic acids; and

[0025] (2) Lipid components, which include ionizable cationic lipids, structural lipids, auxiliary lipids and surfactants.

[0026] In some embodiments, the nucleic acid is selected from mRNA, small interfering RNA (siRNA), DNA, plasmid, antisense oligonucleotide, ribozyme, etc., and the nucleic acid encodes a target therapeutic product, which is complexed with one or more lipids, encapsulated in one or more lipids, or associated with one or more lipids to form lipid nanoparticles.

[0027] In some embodiments, the nucleic acid is selected from an mRNA comprising a nucleotide sequence having at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99% or 100% identity to the nucleotide sequence of any one of SEQ ID NOs: 1-6, or the coronavirus antigen encoded by it comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99% or 100% identity to the amino acid sequence of SEQ ID NO: 7, or it comprises a nucleotide sequence having at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99% or 100% identity to the nucleotide sequence of any one of SEQ ID NOs: 8-26. Preferably, the mRNA comprises the nucleotide sequence of SEQ ID NO: 1, more preferably, the mRNA is the nucleotide sequence of SEQ ID NO: 1.

[0028] In some embodiments, the lipid component includes an ionizable cationic lipid, a structural lipid, a helper lipid, and a surfactant, and the molar content of the ionizable cationic lipid, the structural lipid, the helper lipid, and the surfactant totals 100% by mole. In some embodiments, the lipid component comprises 20-60 mol% ionizable cationic lipid, 25-55 mol% structural lipid, 2-25 mol% helper lipid, and 0.5-15 mol% surfactant.

[0029] In some embodiments, the ionizable cationic lipid is selected from SM-102 (CAS No.: 2089251-47-6), ALC-0315 (CAS No.: 2036272-55-4), Dlin-MC3-DMA (CAS No.: 1224606-06-7), DODMA (CAS No.: 104162-47-2), C12-200 (CAS No.: 1220890-25-4) and DlinDMA (CAS No.: 871258-12-7).

[0030] In some embodiments, the structured lipid is selected from cholesterol or a cholesterol derivative.

[0031] In some embodiments, the helper lipid is selected from distearoylphosphatidylcholine (DSPC), dioleoylphosphatidylethanolamine (DOPE), dioleoylphosphatidylcholine (DOPC), dioleoylphosphatidylglycerol (DOPG), and dioleoylphosphatidylserine (DOPS).

[0032] In some embodiments, the surfactant is selected from mPEG-DMG-2K (CAS No.: 160743-62-4), ALC-0159 (CAS No.: 1849616-42-7), PEGylated distearoylphosphatidylethanolamine (PEG-DSPE), methoxypolyethylene glycol ditetradecylpropylamine (DTDA-PEG2000) and vitamin E polyethylene glycol succinate (TPGS).

[0033] In some embodiments, the lipid composition of the lipid nanoparticle composition comprises 20-50mol% ionizable cationic lipids, preferably 30-50mol% or 40-50mol% ionizable cationic lipids. For example, the lipid composition can comprise 41mol%, 42mol%, 43mol%, 44mol%, 45mol%, 46mol%, 47mol%, 48mol%, 49mol% or 50mol% ionizable cationic lipids (such as SM-102 or Dlin-MC3-DMA). In some embodiments, the lipid composition comprises 50mol% SM-102.

[0034] In other embodiments, the lipid component of the lipid nanoparticle composition comprises 50-60 mol% ionizable cationic lipids. For example, the lipid component can comprise 51 mol%, 52 mol%, 53 mol%, 54 mol%, 55 mol%, 56 mol%, 57 mol%, 58 mol%, 59 mol% or 60 mol% ionizable cationic lipids (such as SM-102 or Dlin-MC3-DMA).

[0035] In some embodiments, the lipid composition of the lipid nanoparticle composition includes 2-25mol% helper lipids, preferably includes 2-20mol% helper lipids, more preferably includes 2-15mol% helper lipids. For example, the lipid composition can include 2mol%, 3mol%, 4mol%, 5mol%, 6mol%, 7mol%, 8mol%, 9mol%, 10mol%, 11mol%, 12mol%, 13mol%, 14mol% or 15mol% helper lipids (such as DSPC). In some embodiments, the lipid composition includes 2-15mol%DSPC. In some embodiments, the lipid composition includes 10mol%DSPC.

[0036] In some embodiments, the lipid component of the lipid nanoparticle composition comprises 25-55 mol% structural lipids, preferably 30-40 mol% structural lipids. For example, the lipid component may comprise 30 mol%, 31 mol%, 32 mol%, 33 mol%, 34 mol%, 35 mol%, 36 mol%, 37 mol%, 38 mol%, 39 mol% or 40 mol% structural lipids (such as cholesterol). In some embodiments, the lipid component comprises 38.5 mol% structural lipids. In some embodiments, the lipid component comprises 38.5 mol% cholesterol.

[0037] In some embodiments, the lipid component of the lipid nanoparticle composition comprises 0.5-15 mol% surfactant, preferably 0.5-10 mol% or 0.5-5 mol% surfactant, more preferably 1-2 mol% surfactant. For example, the lipid component may comprise 1 mol%, 1.5 mol% or 2 mol% surfactant (such as mPEG-DMG-2K). In some embodiments, the lipid component comprises 1.5 mol% mPEG-DMG-2K.

[0038] In some embodiments, the lipid component of the lipid nanoparticle composition comprises 50 mol% ionizable cationic lipid, 10 mol% helper lipid, 38.5 mol% structural lipid, and 1.5 mol% surfactant.

[0039] In some embodiments, the lipid component of the lipid nanoparticle composition comprises 50 mol% SM-102, 10 mol% DSPC, 38.5 mol% cholesterol, and 1.5 mol% mPEG-DMG-2K.

[0040] In some embodiments, the lipid nanoparticles have an N:P ratio of about 2:1 to about 30:1, preferably an N:P ratio of about 2:1 to about 15:1, more preferably about 2:1 to about 10:1, and more preferably about 3:1 to about 6:1. In some embodiments, the lipid nanoparticles have an N:P ratio of about 6:1. In some embodiments, the lipid nanoparticles have an N:P ratio of about 3:1.

[0041] In some embodiments, the weight ratio of the ionizable cationic lipid component to the nucleic acid in the lipid nanoparticle composition is about 5:1 to about 100:1, preferably about 5:1 to about 50:1, preferably about 5:1 to about 30:1, and more preferably about 10:1 to about 20:1. In some embodiments, the weight ratio of the ionizable cationic lipid component to the nucleic acid in the lipid nanoparticle composition is about 20:1. In some embodiments, the weight ratio of the ionizable cationic lipid component to the nucleic acid in the lipid nanoparticle composition is about 10:1.

[0042] In some embodiments, the lipid nanoparticle composition further comprises a finishing buffer.

[0043] In some embodiments, the finished buffer comprises a buffering agent and / or a cryoprotectant.

[0044] In some embodiments, the buffer can be selected from acetate, formate, carbonate, phosphate, borate, succinate, gluconate, lactate, citric acid, glycine, leucine, barbituric acid, phthalic acid, tromethamine (Tris), triethylamine, ammonium salts, and combinations thereof. The content / concentration of the buffer is determined based on the acidity or alkalinity of the specific type of buffer, so that the pH value of the buffer is 7-8.

[0045] In some embodiments, the cryoprotectant can be selected from substances such as sugars, polyols, polymers, surfactants, amino acids and salts, wherein the sugar can be selected from lactose, sucrose, trehalose, galactose and the like.

[0046] In some embodiments, the amount of the cryoprotectant is 1 to 50% w / w of the composition, such as from 2 to 50% w / w, or from 4 to 45% w / w, or from 6 to 12% w / w, preferably from 6 to 10% w / w, most preferably from 7 to 9% w / w.

[0047] In some embodiments, the finished buffer comprises: tromethamine, sodium acetate, sucrose, and has a pH value of 7-8.

[0048] In some embodiments, the content of tromethamine is selected from 10-30mmol / L, preferably 15-25mmol / L, preferably 15-20mmol / L, for example, the content of tromethamine is selected from 15mmol / L, 15.5mmol / L, 16mmol / L, 16.5mmol / L, 17mmol / L, 17.5mmol / L, 18mmol / L, 18.5mmol / L, 19mmol / L, 19.5mmol / L, 20mmol / L, 20.5mmol / L, 21mmol / L, 21.5mmol / L, 22mmol / L, 22.5mmol / L, 23mmol / L, 23.5mmol / L, 24mmol / L, 24.5mmol / L, 25mmol / L, and most preferably 20mmol / L.

[0049] In some embodiments, the content of sodium acetate is selected from 0-20mmol / L, preferably 5-11mmol / L, for example, the content of sodium acetate is selected from 5mmol / L, 5.5mmol / L, 6mmol / L, 6.5mmol / L, 7mmol / L, 7.5mmol / L, 8mmol / L, 8.5mmol / L, 9mmol / L, 9.5mmol / L, 10mmol / L, 10.5mmol / L, 10.6mmol / L, 10.7mmol / L, 10.8mmol / L, 10.9mmol / L, 11mmol / L, 11.5mmol / L, 12mmol / L, 12.5mmol / L, 13mmol / L, and most preferably 10.7mmol / L.

[0050] In some embodiments, the sucrose content is selected from 5-15%, preferably 7.5-10%, more preferably 7.5-9%, for example selected from 7.6%, 7.7%, 7.8%, 7.9%, 8.0%, 8.1%, 8.2%, 8.3%, 8.4%, 8.5%, 9%, 9.5%, 10%, and most preferably 8.7%.

[0051] In some embodiments, the composition comprises lipid nanoparticles encapsulating nucleic acids and a finishing buffer.

[0052] In some embodiments, the composition comprises lipid nanoparticles encapsulating nucleic acids, a finishing buffer, and a cryoprotectant.

[0053] In some embodiments, the composition comprises nucleic acid-encapsulating lipid nanoparticles, tromethamine, sodium acetate, and sucrose.

[0054] In some embodiments, the composition comprises lipid nanoparticles encapsulating nucleic acid, 20 mmol / L tromethamine, 10.7 mmol / L sodium acetate and 8.7% sucrose, and the pH of the composition is 7.0-8.0, wherein the lipid nanoparticles comprise nucleic acid and lipid components, the nucleic acid is mRNA at a concentration of 100 μg / ml, and the lipid component comprises 50 mol% SM-102, 10 mol% DSPC, 38.5 mol% cholesterol and 1.5 mol% mPEG-DMG-2K, and the empty loading rate of the composition is no more than 10%.

[0055] In a second aspect of the present invention, a method for preparing a nucleic acid-encapsulating lipid nanoparticle composition according to the first aspect is provided, comprising: (1) preparing precursor lipid nanoparticles to obtain a buffer system containing the precursor lipid nanoparticles, and (2) replacing the buffer system containing the precursor lipid nanoparticles with a neutral buffer system to obtain a finished lipid nanoparticle composition, wherein, by the buffer system replacement, the content of the organic solvent in the buffer system containing the precursor lipid nanoparticles is reduced to less than or equal to 5% (w / w) when the pH value of the system is lower than the pKa of the lipid nanoparticles by more than 0.5 units.

[0056] Precursor lipid nanoparticles can be prepared by methods known in the art for preparing lipid nanoparticles.

[0057] In some embodiments, precursor lipid nanoparticles can be prepared as follows: dissolving lipid components (ionizable cationic lipids, auxiliary lipids, structural lipids and surfactants) in an organic solvent to form a lipid phase; dissolving nucleic acids in an acidic buffer to form an aqueous phase; and mixing the lipid phase and the aqueous phase to allow the lipids to encapsulate the nucleic acids to form precursor lipid nanoparticles.

[0058] In some embodiments, precursor lipid nanoparticles can also be prepared as follows: dissolving lipid components (ionizable cationic lipids, auxiliary lipids, structural lipids and surfactants) in an organic solvent to form a lipid phase, mixing the lipid phase and an acidic buffer to form blank lipid nanoparticles; dissolving nucleic acids in an acidic buffer to form an aqueous phase; and mixing the blank lipid nanoparticles with the aqueous phase containing nucleic acids to allow the lipids to encapsulate the nucleic acids to form precursor lipid nanoparticles.

[0059] In the above embodiment, the organic solvent is selected from C1 to C4 low-carbon alcohols, preferably ethanol.

[0060] In the above embodiment, the total concentration of lipid components (ionizable cationic lipids, structural lipids, auxiliary lipids and surfactants) in the lipid phase is 10-15 mg / ml.

[0061] In the above embodiment, the concentration of nucleic acid in the aqueous phase is 0.01-1 mg / ml, preferably 0.05-0.5 mg / ml, more preferably 0.1-0.2 mg / ml.

[0062] In the above embodiments, the acidic buffer comprises a buffer selected from the group consisting of acetate, formate, carbonate, phosphate, borate, succinate, gluconate, lactate, citric acid, glycine, leucine, barbituric acid, phthalic acid, tromethamine (Tris), triethylamine, ammonium salts, and combinations thereof. The content / concentration of the buffer is determined based on the acidity or alkalinity of the specific type of buffer, such that the pH of the acidic buffer is less than the pKa of the lipid nanoparticles. In some embodiments, the acidic buffer further comprises an osmotic pressure regulator selected from sodium chloride, potassium chloride, and the like.

[0063] In some embodiments, the acidic buffer comprises citric acid and sodium chloride. Preferably, the acidic buffer comprises 10-20 mM citric acid and 120-140 mM sodium chloride. In some embodiments, the acidic buffer comprises 10 mM citric acid and 130 mM sodium chloride, and has a pH of 3.9-4.1, for example, a pH of 4.0. In some embodiments, the acidic buffer comprises 20 mM citric acid and 130 mM sodium chloride, and has a pH of 3.9-4.1, for example, a pH of 4.0. Preferably, in some embodiments, the acidic buffer comprises 10 mM citric acid and 130 mM sodium chloride, and has a pH of 4.0; or, comprises 20 mM citric acid and 130 mM sodium chloride, and has a pH of 4.0.

[0064] In the above embodiment, the volume ratio of the fat phase and the water phase is 1:2-1:9, preferably 1:2-1:5, preferably 1:3.

[0065] In the above embodiment, the mixing is performed by a microfluidic mixer, and the microfluidic mixer is selected from a staggered herringbone mixer (SHM), a T-junction mixer (T-Junction Mixer), and a microfluidic hydrodynamic focusing (MHF).

[0066] In the above embodiment, the particle size of the prepared precursor lipid nanoparticles is 20-150 nm, preferably 30-100 nm, more preferably 40-90 nm, and even more preferably 50-80 nm.

[0067] In the above embodiment, the particle dispersion index (PDI) of the prepared precursor lipid nanoparticles is 0.01-0.3, preferably 0.01-0.2, and more preferably 0.01-0.15.

[0068] In the above embodiment, the encapsulation efficiency of the prepared precursor lipid nanoparticles is 50-100%, preferably 80%-100%, and more preferably 90%-100%.

[0069] After the precursor lipid nanoparticles are prepared, the buffer system containing the precursor lipid nanoparticles is replaced with a neutral buffer system to obtain a finished lipid nanoparticle composition.

[0070] In some embodiments, the buffer system replacement comprises a two-stage buffer system replacement process.

[0071] In some embodiments, the two-stage buffer system replacement process includes: using an acidic buffer or a neutral buffer for replacement in the first stage, and using a neutral buffer for replacement in the second stage. In this process, the pH value of the system is maintained below the pKa of the lipid nanoparticles in the first stage, and the organic solvent content in the system is reduced to a certain level (for example, less than or equal to 5%) by replacement with an acidic buffer or a neutral buffer to ensure that when the particles fuse in the second stage, the organic solvent residue in the system is low; in the second stage, when the pH value of the system is increased to near the pKa of the lipid nanoparticles by replacement with a neutral buffer, the particles begin to fuse, and the low organic solvent content allows for more complete particle fusion; when the pH value of the system is higher than the pKa of the lipid nanoparticles, the particle fusion is complete, forming thermodynamically stable particles (i.e., finished lipid nanoparticles).

[0072] In the above embodiments, the acidic buffer comprises a buffer selected from the group consisting of acetate, formate, carbonate, phosphate, borate, succinate, gluconate, lactate, citric acid, glycine, leucine, barbituric acid, phthalic acid, tromethamine (Tris), triethylamine, ammonium salts, and combinations thereof. The amount / concentration of the buffer is determined based on the acidity or alkalinity of the specific type of buffer, such that the pH of the acidic buffer is less than the pKa of the lipid nanoparticles. In some embodiments, the pKa of the lipid nanoparticles is 6.0-7.0, and the pH of the acidic buffer is less than the pKa of the lipid nanoparticles, for example, a pH of 3.0-5.0, preferably 4.0-5.0.

[0073] In some embodiments, the acidic buffer further comprises an osmotic pressure regulator, and the osmotic pressure regulator is selected from sodium chloride, potassium chloride, and the like.

[0074] In some embodiments, the acidic buffer comprises citric acid and sodium chloride. Preferably, the acidic buffer comprises 10-20 mM citric acid and 120-140 mM sodium chloride. In some embodiments, the acidic buffer comprises 10 mM citric acid and 130 mM sodium chloride, and has a pH of 3.9-4.1, for example, a pH of 4.0. Preferably, in some embodiments, the acidic buffer comprises 10 mM citric acid and 130 mM sodium chloride, and has a pH of 4.0.

[0075] In the above embodiments, the neutral buffer comprises a buffer selected from the group consisting of acetate, formate, carbonate, phosphate, borate, succinate, gluconate, lactate, citric acid, glycine, leucine, barbituric acid, phthalic acid, tromethamine (Tris), triethylamine, ammonium salts, and combinations thereof. The amount / concentration of the buffer is determined based on the acidity or alkalinity of the specific type of buffer, such that the pH of the neutral buffer is greater than the pKa of the lipid nanoparticles. In some embodiments, the pKa of the lipid nanoparticles is between 6.0 and 7.0, and the pH of the neutral buffer is greater than the pKa of the lipid nanoparticles, for example, between 7.0 and 8.0.

[0076] In some embodiments, the neutral buffer further comprises a cryoprotectant, which can be selected from sugars, polyols, polymers, surfactants, amino acids, and salts, wherein the sugar can be selected from lactose, sucrose, trehalose, galactose, and the like.

[0077] In some embodiments, the amount of the cryoprotectant is from 1% w / w to 50% w / w of the buffer, such as from 2% w / w to 50% w / w, or from 4% w / w to 45% w / w, or from 6% w / w to 12% w / w, preferably from 6% w / w to 10% w / w, most preferably from 7% w / w to 9% w / w.

[0078] In some embodiments, the neutral buffer comprises tromethamine, sodium acetate, and sucrose, and has a pH of 7-8.

[0079] In some embodiments, the content of tromethamine is selected from 10-30mmol / L, preferably 15-25mmol / L, preferably 15-20mmol / L, for example, the content of tromethamine is selected from 15mmol / L, 15.5mmol / L, 16mmol / L, 16.5mmol / L, 17mmol / L, 17.5mmol / L, 18mmol / L, 18.5mmol / L, 19mmol / L, 19.5mmol / L, 20mmol / L, 20.5mmol / L, 21mmol / L, 21.5mmol / L, 22mmol / L, 22.5mmol / L, 23mmol / L, 23.5mmol / L, 24mmol / L, 24.5mmol / L, 25mmol / L, and most preferably 20mmol / L.

[0080] In some embodiments, the content of sodium acetate is selected from 0-20mmol / L, preferably 5-11mmol / L, for example, the content of sodium acetate is selected from 5mmol / L, 5.5mmol / L, 6mmol / L, 6.5mmol / L, 7mmol / L, 7.5mmol / L, 8mmol / L, 8.5mmol / L, 9mmol / L, 9.5mmol / L, 10mmol / L, 10.5mmol / L, 10.6mmol / L, 10.7mmol / L, 10.8mmol / L, 10.9mmol / L, 11mmol / L, 11.5mmol / L, 12mmol / L, 12.5mmol / L, 13mmol / L, and most preferably 10.7mmol / L.

[0081] In some embodiments, the sucrose content is selected from 5%-15%, preferably 7.5%-10%, more preferably 7.5%-9%, for example selected from 7.6%, 7.7%, 7.8%, 7.9%, 8.0%, 8.1%, 8.2%, 8.3%, 8.4%, 8.5%, 8.6%, 8.7%, 8.8%, 8.9%, 9%, 9.5%, 10%, and most preferably 8.7%.

[0082] In some embodiments, the neutral buffer comprises 20 mM Tris, 10.7 mM NaOAc and 8.7% sucrose, with a pH of 7.4-7.6. Preferably, in some embodiments, the neutral buffer comprises 20 mM Tris, 10.7 mM NaOAc and 8.7% sucrose, with a pH of 7.6.

[0083] The above neutral buffer components remain in the product, also known as finished buffer.

[0084] In some embodiments, the replacement process is selected from one or more of tangential flow filtration, membrane dialysis, column dialysis, and dilution.

[0085] In some embodiments, the two-stage buffer system replacement process includes dialysis using an acidic buffer or a neutral buffer in the first stage, and dialysis using a neutral buffer in the second stage.

[0086] In some embodiments, the two-stage buffer exchange process includes dilution with an acidic buffer in the first stage and dialysis with a neutral buffer in the second stage.

[0087] In some embodiments, the two-stage buffer system replacement process can be repeated multiple times, that is, the pH value can be increased and decreased alternately multiple times.

[0088] In the two-stage buffer system replacement process of the above embodiment, at the end of the first stage, the organic solvent content in the buffer system containing the precursor lipid nanoparticles is reduced to less than or equal to 5% (w / w), preferably less than 3% (w / w).

[0089] In the two-stage buffer exchange process of the above embodiment, at the end of the first stage, the pH of the buffer system containing the precursor lipid nanoparticles is at least 0.5 units lower than the pKa of the lipid nanoparticles. For example, in some embodiments, the pKa of the lipid nanoparticles is 6.0-7.0, and at the end of the first stage of the two-stage buffer exchange process, the pH of the buffer system is at least 0.5 units lower than the pKa of the lipid nanoparticles, for example, at pH 5.0-6.0.

[0090] In the two-stage buffer system replacement process of the above embodiment, at the end of the second stage, the organic solvent content in the buffer system containing the finished lipid nanoparticles is reduced to less than 1% (w / w), preferably less than 0.1% (w / w).

[0091] In the two-stage buffer exchange process of the above embodiment, at the end of the second stage, the pH of the buffer system containing the finished lipid nanoparticles is at least 0.5 units higher than the pKa of the lipid nanoparticles. For example, in some embodiments, the pKa of the lipid nanoparticles is 6.0-7.0, and at the end of the second stage of the two-stage buffer exchange process, the pH of the buffer system is at least 0.5 units higher than the pKa of the lipid nanoparticles, for example, pH 7.0-8.0.

[0092] In some embodiments, the buffer system replacement includes a two-step buffer dialysis process. In some embodiments, the two-step buffer dialysis process includes using an acidic buffer for replacement in the first stage and a neutral buffer for replacement in the second stage; or using a neutral buffer for replacement in the first stage and another neutral buffer for replacement in the second stage. The acidic buffer and the neutral buffer are as described above. In this process, the organic solvent content in the system is reduced to a certain level (for example, less than or equal to 5%) when the pH value of the system is lower than the pKa of the lipid nanoparticles by more than 0.5 units through the first stage replacement, thereby ensuring that the organic solvent residue in the system is low when the particles fuse; when the pH value of the system is raised to near the pKa of the lipid nanoparticles in the second stage replacement, the particles begin to fuse, and the particles fuse more fully at low organic solvent content; when the pH value of the system is higher than the pKa of the lipid nanoparticles, the particle fusion is completed to form thermodynamically stable particles (i.e., finished lipid nanoparticles).

[0093] In some embodiments, the buffer system replacement uses only one neutral buffer for dialysis (a one-step buffer dialysis process). The neutral buffer is as described above. Although this process uses only one neutral buffer, the pH value and buffering capacity of the neutral buffer can be controlled so that the organic solvent content in the system is reduced to a certain level (e.g., less than or equal to 5%) when the pH value of the system is lower than the pKa of the lipid nanoparticles by more than 0.5 units during the dialysis process (i.e., the first stage replacement); the neutral buffer is continued to be used for dialysis (the second stage replacement). When the pH value of the system rises to near the pKa of the lipid nanoparticles, the particles begin to fuse. At low organic solvent content, the particles fuse more fully; when the pH value of the system is higher than the pKa of the lipid nanoparticles, the particle fusion is completed to form thermodynamically stable particles (i.e., finished lipid nanoparticles).

[0094] In a specific embodiment, the method for preparing a lipid nanoparticle composition encapsulating nucleic acid described in the present invention comprises the following steps: (1) dissolving lipid components (ionizable cationic lipids, auxiliary lipids, structural lipids and surfactants) in an organic solvent to form a lipid phase; (2) dissolving nucleic acid in an acidic buffer to form an aqueous phase; (3) mixing the lipid phase and the aqueous phase to form lipid-encapsulated nucleic acid to form precursor lipid nanoparticles; and (4) replacing the organic solvent-acidic buffer system containing the precursor lipid nanoparticles obtained in step (3) with a neutral buffer system in two stages to obtain a finished lipid nanoparticle composition: the first stage is replaced with an acidic buffer or a neutral buffer; the second stage is replaced with a neutral buffer. In the first stage, the pH value of the system is maintained below the pKa of the lipid nanoparticles, and the organic solvent content in the system is reduced to a certain level through acidic buffer or neutral buffer replacement to ensure that when the particles fuse in the second stage, the residual organic solvent in the system is low; in the second stage, through neutral buffer replacement, when the pH value of the system rises to near the pKa of the lipid nanoparticles, the particles begin to fuse, and under low organic solvent content, the particles fuse more completely; when the pH value of the system is higher than the pKa of the lipid nanoparticles, the particle fusion is completed, forming thermodynamically stable particles (i.e., finished lipid nanoparticles).

[0095] In some embodiments, the organic solvent in step (1) is selected from C1-C4 low-carbon alcohols, preferably ethanol.

[0096] In some embodiments, the total concentration of lipid components (ionizable cationic lipids, structural lipids, auxiliary lipids and surfactants) in the lipid phase in step (1) is 10-15 mg / ml.

[0097] In some embodiments, the concentration of nucleic acid in the aqueous phase in step (2) is 0.01-1 mg / ml, preferably 0.05-0.5 mg / ml, and more preferably 0.1-0.2 mg / ml.

[0098] In some embodiments, the acidic buffer described in step (2) or step (4) comprises a buffer selected from the group consisting of acetate, formate, carbonate, phosphate, borate, succinate, gluconate, lactate, citric acid, glycine, leucine, barbituric acid, phthalic acid, tromethamine (Tris), triethylamine, ammonium salts, and combinations thereof. The content / concentration of the buffer is determined based on the acidity or alkalinity of the specific type of buffer, such that the pH of the acidic buffer is less than the pKa of the lipid nanoparticles. In some embodiments, the pKa of the lipid nanoparticles is 6.0-7.0, and the pH of the acidic buffer described in step (2) or step (4) is less than the pKa of the lipid nanoparticles, for example, a pH of 3.0-5.0, preferably 4.0-5.0.

[0099] In some embodiments, the acidic buffer solution in step (2) or step (4) further comprises an osmotic pressure regulator, and the osmotic pressure regulator is selected from sodium chloride, potassium chloride, and the like.

[0100] In some embodiments, the acidic buffer in step (2) or step (4) comprises citric acid and sodium chloride. Preferably, the buffer comprises 10-20 mM citric acid and 120-140 mM sodium chloride.

[0101] In some embodiments, the acidic buffer described in step (2) or step (4) comprises 10 mM citric acid and 130 mM sodium chloride, and has a pH of 3.9-4.1, for example, a pH of 4.0. In some embodiments, the acidic buffer described in step (2) or step (4) comprises 20 mM citric acid and 130 mM sodium chloride, and has a pH of 3.9-4.1, for example, a pH of 4.0. Preferably, in some embodiments, the acidic buffer described in step (2) or step (4) comprises 10 mM citric acid and 130 mM sodium chloride, and has a pH of 4.0; or, comprises 20 mM citric acid and 130 mM sodium chloride, and has a pH of 4.0.

[0102] In some embodiments, the volume ratio of the lipid phase and the aqueous phase mixed in step (3) is 1:2-1:9, preferably 1:2-1:5, preferably 1:3.

[0103] In some embodiments, the lipid phase and the aqueous phase in step (3) are mixed by a microfluidic mixer, and the microfluidic mixer is selected from a staggered herringbone mixer (SHM), a T-junction mixer (T-Junction Mixer), and a microfluidic hydrodynamic focusing (MHF).

[0104] In some embodiments, the particle size of the precursor lipid nanoparticles in step (3) is 20-150 nm, preferably 30-100 nm, or 40-90 nm, or 50-80 nm.

[0105] In some embodiments, the particle dispersion index (PDI) of the precursor lipid nanoparticles in step (3) is 0.01-0.3, preferably 0.01-0.2, and more preferably 0.01-0.15.

[0106] In some embodiments, the encapsulation efficiency of the precursor lipid nanoparticles in step (3) is 50-100%, preferably 80%-100%, and more preferably 90%-100%.

[0107] In some embodiments, the replacement process in step (4) is selected from one or more of tangential flow filtration, membrane dialysis, column dialysis, and dilution.

[0108] In some embodiments, in the two-stage replacement process in step (4), at the end of the first stage, the organic solvent content in the buffer system containing the precursor lipid nanoparticles is reduced to less than or equal to 5% (w / w), preferably less than 3% (w / w).

[0109] In some embodiments, at the end of the first stage of the two-stage displacement process in step (4), the pH of the buffer system containing the precursor lipid nanoparticles is at least 0.5 units lower than the pKa of the lipid nanoparticles. For example, in some embodiments, the pKa of the lipid nanoparticles is 6.0-7.0, and at the end of the first stage of the two-stage displacement process in step (4), the pH of the buffer system is at least 0.5 units lower than the pKa of the lipid nanoparticles, for example, a pH of 5.0-6.0.

[0110] In some embodiments, in the two-stage replacement process of step (4), at the end of the second stage, the organic solvent content in the buffer system containing the finished lipid nanoparticles is reduced to less than 1% (w / w), preferably less than 0.1% (w / w).

[0111] In some embodiments, at the end of the second stage of the two-stage displacement process in step (4), the pH of the buffer system containing the finished lipid nanoparticles is greater than the pKa of the lipid nanoparticles by more than 0.5 units. For example, in some embodiments, the pKa of the lipid nanoparticles is 6.0-7.0, and at the end of the second stage of the two-stage displacement process in step (4), the pH of the buffer system is greater than the pKa of the lipid nanoparticles by more than 0.5 units, for example, 7.0-8.0.

[0112] In some embodiments, the two-stage replacement process described in step (4) can be repeated multiple times, that is, step (4) can be a process of alternating multiple increases and decreases in pH. Crossing the pKa of the lipid nanoparticles can enhance the particle fusion effect.

[0113] In some embodiments, the neutral buffer described in step (4) comprises a buffer selected from the group consisting of acetate, formate, carbonate, phosphate, borate, succinate, gluconate, lactate, citric acid, glycine, leucine, barbituric acid, phthalic acid, tromethamine (Tris), triethylamine, ammonium salts, and combinations thereof. The content / concentration of the buffer is determined based on the acidity or alkalinity of the specific type of buffer, such that the pH of the neutral buffer is greater than the pKa of the lipid nanoparticles. In some embodiments, the pKa of the lipid nanoparticles is 6.0-7.0, and the pH of the neutral buffer described in step (4) is greater than the pKa of the lipid nanoparticles, for example, a pH of 7.0-8.0.

[0114] In some embodiments, the neutral buffer in step (4) further comprises a cryoprotectant. The cryoprotectant can be selected from sugars, polyols, polymers, surfactants, amino acids, and salts, wherein the sugar can be selected from lactose, sucrose, trehalose, galactose, and the like.

[0115] In some embodiments, the amount of the cryoprotectant is from 1% w / w to 50% w / w of the buffer, such as from 2% w / w to 50% w / w, or from 4% w / w to 45% w / w, or from 6% w / w to 12% w / w, preferably from 6% w / w to 10% w / w, most preferably from 7% w / w to 9% w / w.

[0116] In some embodiments, the neutral buffer comprises tromethamine, sodium acetate, and sucrose, and has a pH value of 7-8.

[0117] In some embodiments, the content of tromethamine is selected from 10-30mmol / L, preferably 15-25mmol / L, preferably 15-20mmol / L, for example, the content of tromethamine is selected from 15 mmol / L, 15.5mmol / L, 16mmol / L, 16.5mmol / L, 17mmol / L, 17.5mmol / L, 18mmol / L, 18.5mmol / L, 19mmol / L, 19.5mmol / L, 20mmol / L, 20.5mmol / L, 21mmol / L, 21.5mmol / L, 22mmol / L, 22.5mmol / L, 23mmol / L, 23.5mmol / L, 24mmol / L, 24.5mmol / L, 25mmol / L, most preferably 20mmol / L.

[0118] In some embodiments, the content of sodium acetate is selected from 0-20mmol / L, preferably 5-11mmol / L, for example, the content of sodium acetate is selected from 5mmol / L, 5.5mmol / L, 6mmol / L, 6.5mmol / L, 7mmol / L, 7.5mmol / L, 8mmol / L, 8.5mmol / L, 9mmol / L, 9.5mmol / L, 10mmol / L, 10.5mmol / L, 10.6mmol / L, 10.7mmol / L, 10.8mmol / L, 10.9mmol / L, 11mmol / L, 11.5mmol / L, 12mmol / L, 12.5mmol / L, 13mmol / L, and most preferably 10.7mmol / L.

[0119] In some embodiments, the sucrose content is selected from 5%-15%, preferably 7.5%-10%, more preferably 7.5%-9%, for example selected from 7.6%, 7.7%, 7.8%, 7.9%, 8.0%, 8.1%, 8.2%, 8.3%, 8.4%, 8.5%, 8.6%, 8.7%, 8.8%, 8.9%, 9%, 9.5%, 10%, and most preferably 8.7%.

[0120] In some embodiments, the neutral buffer in step (4) comprises 20 mM Tris, 10.7 mM NaOAc and 8.7% sucrose, with a pH of 7.4-7.6. Preferably, in some embodiments, the neutral buffer in step (4) comprises 20 mM Tris, 10.7 mM NaOAc and 8.7% sucrose, with a pH of 7.6.

[0121] The neutral buffer component of the above step (4) remains in the product, also known as finished buffer.

[0122] In some embodiments, the above preparation method optionally includes step (5) of concentration, dilution, sterile filtration, aseptic filling, and combinations thereof. The concentration, dilution, and aseptic filling steps are used to ensure that the nucleic acid drug reaches the specifications and dosage for administration, and the sterile filtration step is used to ensure that the microbial properties of the nucleic acid drug meet the requirements.

[0123] The key process steps of the method for preparing the nucleic acid lipid nanoparticle composition of the present invention are: preparation of precursor lipid nanoparticles (lipid-water phase mixing) and buffer exchange. The formation of thermodynamically stable nucleic acid lipid nanoparticles relies on the particle fusion process during the buffer exchange process. Reducing the organic solvent content in the system to less than or equal to 5% (w / w) before particle fusion facilitates sufficient particle fusion, thereby obtaining thermodynamically stable lipid nanoparticles. Advantageously, through buffer exchange, the organic solvent content in the buffer system containing the precursor lipid nanoparticles is reduced to less than or equal to 5% (w / w) when the pH of the system is at least 0.5 units below the pKa of the lipid nanoparticles.

[0124] Beneficial effects of the present invention

[0125] The present application provides a new method for improving the stability and in vivo behavior of nucleic acid drugs by increasing the degree of fusion of particles during the preparation process to obtain a low empty load rate of encapsulated nucleic acid lipid nanoparticles. The particle morphology and structure after full fusion are more uniform, the particles are more stable, and the prepared mRNA LNPs can be stored for at least 6 months under 2-8°C refrigeration conditions and at least 12 months under -15°C to -25°C freezing conditions. The stability is significantly better than that of drugs already on the market, and it is convenient for storage, transportation and circulation. Compared with the particles prepared by traditional methods, the nucleic acid lipid nanoparticles with low empty load rate of the present invention are basically all the payloads of encapsulated nucleic acid, which is beneficial to improve the efficiency of nucleic acid delivery, reduce the risk of inflammatory adverse reactions caused by lipid components, and improve the effectiveness and safety of nucleic acid drugs. In addition, the nucleic acid lipid nanoparticles with such low empty load rate are more likely to be retained at the injection site, and their distribution in the blood and non-target organs (such as the heart) is reduced, reducing the risk of adverse reactions caused by distribution in non-target organs.

[0126] Terminology

[0127] Unless otherwise indicated, the following terms used in the specification and claims of this application have the following meanings. It should be understood that, unless expressly defined herein, a term shall be given its meaning as commonly understood in the art. Further, it should be understood that the terminology used herein is for the purpose of describing specific embodiments only and is not intended to limit the scope of the present invention in any way.

[0128] Ionizable cationic lipids

[0129] The term "ionizable cationic lipid" used in this article refers to a special lipid that is ionizable and positively charged under acidic conditions below the pKa. It can complex with negatively charged RNA so that it is encapsulated in LNP for protection; it is uncharged under physiological conditions where the pKa is neutral and higher, making the LNP electrically neutral and having the ability to be low-toxic and invisible, thereby carrying RNA into the cell through the endosomal pathway; in the acidic endosomes, the ionizable cationic lipid switches to a positive charge, interacts with the negatively charged phospholipids on the endosomal membrane and destroys the endosomes, achieving endosomal escape and the release of RNA in the cytoplasm.

[0130] pKa of lipid nanoparticles

[0131] As used herein, the term "pKa of a lipid nanoparticle" refers to the apparent ionization constant of a lipid nanoparticle comprising a specific ionizable cationic lipid. The pKa value of a lipid nanoparticle comprising a specific ionizable cationic lipid is related to the tolerability of the lipid nanoparticle at the injection site, its safety and stability in vivo, and its intracellular delivery efficacy. The pKa value of lipid nanoparticles comprising a specific ionizable cationic lipid can be determined using the 6-(p-toluidinyl)-2-sulfonic acid sodium salt (TNS) probe commonly used in literature reports. During titration, the pH value corresponding to the point at which the TNS fluorescence signal changes with pH is the pKa value of the lipid nanoparticle comprising the ionizable cationic lipid.

[0132] Precursor lipid nanoparticles

[0133] The term "precursor lipid nanoparticles" used herein refers to an intermediate form of lipid nanoparticles present in the preparation process of LNPs containing ionizable cationic lipids, which are self-assembled by rapid mixing of lipids in the organic phase and nucleic acids in the aqueous phase. After mixing, since the pH value of the system is significantly lower than the pKa of the ionizable cationic lipids, the ionizable cationic lipids are protonated and positively charged, and electrostatic attraction is generated between them and the negatively charged nucleic acids. At the same time, due to the poor water solubility of the lipids, hydrophobic interactions are generated, driving the lipid-encapsulated nucleic acids to self-assemble into precursor lipid nanoparticles. In the subsequent dialysis or ultrafiltration process, the precursor lipid nanoparticles fuse with changes in the pH value of the system to form finished lipid nanoparticles.

[0134] N:P ratio

[0135] As used herein, the term "N:P ratio" refers to the molar ratio of the protonatable nitrogen element of the ionizable cationic lipid to the phosphate groups of the mRNA. The N:P ratio describes the molar ratio of the amino groups (N + ) and the phosphate groups (PO4 -The ratio of the anionic charges of the lipids (N:P) and the anionic charges of the lipids (N:P) forms the basis for the electrostatic complexation between ionizable cationic lipids and nucleic acids. The N:P ratio is a key formulation factor for LNPs, influencing their physicochemical properties and in vivo drug release.

[0136] Encapsulation efficiency

[0137] The term "encapsulation efficiency" as used herein refers to the proportion of nucleic acids encapsulated within lipid nanoparticles to the total nucleic acids. Encapsulation efficiency is typically measured using fluorescence spectrophotometry. For RNA, the amount of RNA free outside the lipid nanoparticles in the LNP-RNA solution is first detected using RiboGreen fluorescent dye. Triton-100 is then used to disrupt the lipid nanoparticle structure, releasing the RNA into the external solution. The total amount of RNA in the solution is then measured. The difference between the two values ​​is the amount of RNA encapsulated within the LNP particles, providing the encapsulation efficiency.

[0138] No-load rate

[0139] As used herein, the term "empty loading rate" refers to the proportion of lipid nanoparticles that do not encapsulate nucleic acids to the total number of lipid nanoparticles. In the present invention, the empty loading rate is determined using nanoflow cytometry. First, the total number of lipid nanoparticles in a sample is measured using nanoflow cytometry. Ribozymes are then added to the sample to remove free nucleic acids. A transmembrane nucleic acid dye is then added. The dye penetrates the LNP membrane and binds to the nucleic acids within the LNP, generating fluorescence. The number of lipid nanoparticles encapsulating nucleic acids is determined, and the proportion of LNPs that do not encapsulate nucleic acids is calculated, which is the empty loading rate.

[0140] Nucleic Acids

[0141] The terms "nucleic acid" or "nucleic acid molecule" have meanings recognized and understood by those of ordinary skill in the art. The term "nucleic acid," as used herein, refers to a polymer comprising at least two deoxyribonucleotides or ribonucleotides in single-stranded or double-stranded form, including DNA and RNA. DNA can take the form of, for example, antisense molecules, plasmid DNA, pre-condensed DNA, PCR products, vectors (P1, PAC, BAC, YAC, artificial chromosomes), expression cassettes, chimeric sequences, chromosomal DNA, or derivatives and combinations thereof. RNA can take the form of siRNA, asymmetric interfering RNA (aiRNA), microRNA (miRNA), mRNA, tRNA, rRNA, tRNA, viral RNA (vRNA), or combinations thereof. Nucleic acids include those containing known nucleotide analogs or modified backbone residues or bonds, whether synthetic, naturally occurring, or non-naturally occurring, and having binding properties similar to a reference nucleic acid. Examples of such analogs include, but are not limited to, phosphorothioates, phosphoramidates, methylphosphonates, chiral-methylphosphonates, 2'-O-methyl ribonucleotides, and peptide-nucleic acids (PNAs). Unless otherwise specified, the term includes nucleic acids containing known analogs of natural nucleotides that have similar binding properties as the reference nucleic acid. Unless otherwise specified, a particular nucleic acid sequence also inherently includes conservatively modified variants thereof (e.g., degenerate codon substitutions), alleles, orthologs, SNPs, and complementary sequences as well as the sequence explicitly indicated. In particular, degenerate codon substitutions can be achieved by generating sequences in which the third position of one or more selected (or all) codons is replaced by mixed basic and / or deoxyinosine residues (Batzer et al., Nucleic Acid Res., 19:5081 (1991); Ohtsuka et al., J. Biol. Chem., 260:2605-2608 (1985); Rossolini et al., Mol. Cell. Probes, 8:91-98 (1994)). "Nucleotide" comprises deoxyribonucleic acid (DNA) or ribonucleic acid (RNA), a base, and a phosphate group. Nucleotides are linked together by the phosphate group. "Bases" include purines and pyrimidines, which further include the natural compounds adenine, thymine, guanine, cytosine, uracil, inosine, and natural analogs, as well as synthetic derivatives of purines and pyrimidines, which include, but are not limited to, modifications that place new reactive groups such as, but not limited to, amines, alcohols, thiols, carboxylates, and alkyl halides.

[0142] The type of DNA that can be used in this application is not particularly limited and can be appropriately selected according to the purpose of use. Examples thereof include plasmid DNA, cDNA, antisense DNA, chromosomal DNA, PAC, BAC, etc., preferably plasmid DNA, cDNA, antisense DNA, and more preferably plasmid DNA. Circular DNA such as plasmid DNA can also be digested with restriction enzymes and used in the form of linear DNA.

[0143] The types of RNA that can be used in the present application are not particularly limited and can be appropriately selected according to the purpose of use. Examples include siRNA, miRNA, shRNA, antisense RNA, messenger RNA (mRNA), single-stranded RNA genome, double-stranded RNA genome, RNA replicon, transfer RNA, ribosomal RNA, etc., preferably siRNA, miRNA, shRNA, mRNA, antisense RNA, and RNA replicon.

[0144] The source of the nucleic acid that can be used in this application is not particularly limited and can be appropriately selected according to the purpose of use, for example, using commercially available nucleic acid products, or preparing with reference to the methods disclosed in the prior art. In some embodiments, the mRNA used in this application is prepared with reference to the method described in Chinese patent application 202111445859.X filed on November 30, 2021, and the entire contents disclosed in the above patent application are incorporated herein in their entirety for all purposes.

[0145] Although the numerical ranges and parameter approximations shown in the present invention are within a wide range, the numerical values ​​shown in the specific embodiments are recorded as accurately as possible. However, any numerical value is necessarily inherently subject to certain errors, which are caused by the standard deviations present in their respective measurements. In addition, all ranges disclosed herein should be understood to encompass any and all subranges contained therein. For example, a range of "1 to 10" should be considered to include any and all subranges between a minimum of 1 and a maximum of 10 (including endpoints); that is, all subranges starting with a minimum of 1 or greater, such as 1 to 6.1, and subranges terminating with a maximum of 10 or less, such as 5.5 to 10. In addition, any reference referred to as "incorporated herein" should be understood to be incorporated in its entirety.

[0146] In order to provide a more concise description, some quantitative data in this article do not use the term "about". It should be understood that, regardless of whether the term "about" is explicitly used or not, each numerical value given here includes not only the actual given value (given value), but also means to include an approximate value of such given value reasonably inferred by a person of ordinary skill in the art, including equivalents and approximate values ​​of such given value resulting from experimental and / or measurement conditions. The approximate value is preferably ±20%, ±15%, ±10%, ±8%, ±6%, ±5%, ±4%, ±3%, 2%, ±1% based on the given value.

[0147] It should also be noted that as used in this specification, singular forms include plural forms of their referents unless clearly and unambiguously limited to one referent. The term "or" can be used interchangeably with the term "and / or" unless the context clearly indicates otherwise.

[0148] The skilled person will appreciate that any existing or future appropriate method can be used to measure the particle size of the particles, including but not limited to sedimentation methods, screening methods, microscopic observation, or laser particle size measurement. It should also be understood that when there are multiple nanoparticles disclosed herein, not all of the nanoparticles have the same particle size; as long as their average particle size meets the above-mentioned limitations, they are included within the scope encompassed by the present disclosure. In some specific embodiments, the particle size is determined using a laser particle size measurement instrument.

[0149] Other embodiments of the present invention include:

[0150] 1. A lipid nanoparticle composition for encapsulating nucleic acids, characterized in that the ratio of empty lipid nanoparticles containing no nucleic acid to the total number of lipid nanoparticles, i.e., an empty loading rate is no more than 10%, preferably an empty loading rate is no more than 9%, more preferably an empty loading rate is no more than 8.5%, more preferably an empty loading rate is no more than 6%, and further preferably an empty loading rate is no more than 3%, or any value within the above range, for example, an empty loading rate of 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 7.1%, 7.6%, 7.7%, 7.9%, 8.3%.

[0151] 2. The composition of Scheme 1, wherein the average particle size of the lipid nanoparticles is 50 nm to 150 nm, preferably 70 nm to 120 nm, more preferably 90 nm to 110 nm, or any value within the above range, for example, the average particle size is 96 nm, 97 nm, 98 nm, 99 nm, 100 nm, 101 nm, 102 nm, 103 nm, 104 nm, 105 nm, 106 nm, 107 nm, 109 nm, 110 nm, 111 nm, 112 nm, 113 nm, 114 nm, 115 nm, 116 nm, 117 nm, 119 nm, or 120 nm.

[0152] 3. The composition as described in Scheme 1 is characterized in that the encapsulation efficiency of the lipid nanoparticles is above 80%, preferably above 85%, and more preferably above 90%.

[0153] 4. The composition as described in Scheme 1 is characterized in that the nanoparticles contain (1) nucleic acid, and (2) lipid components: including ionizable cationic lipids, auxiliary lipids, structural lipids and surfactants.

[0154] 5. The composition as described in Scheme 4 is characterized in that the lipid component contains 20-60 mol% ionizable cationic lipids, 25-55 mol% structural lipids, 2-25 mol% auxiliary lipids and 0.5-15 mol% surfactants.

[0155] 6. A composition as described in Scheme 5, characterized in that the cationic lipid is selected from SM-102, ALC-0315, Dlin-MC3-DMA, DODMA, C12-200 and DlinDMA, the structural lipid is selected from cholesterol or cholesterol derivatives, the auxiliary lipid is selected from DSPC, DOPE, DOPC, DOPG and DOPS, and the surfactant is selected from mPEG-DMG-2K, ALC-0159, PEG-DSPE, DTDA-PEG2000 and TPGS.

[0156] 7. The composition of Scheme 5, wherein the lipid nanoparticles have an N:P ratio of about 2:1 to about 30:1, preferably an N:P ratio of about 2:1 to about 15:1, more preferably about 2:1 to about 10:1, and even more preferably about 3:1 to about 6:1.

[0157] 8. A composition as described in Scheme 4, characterized in that the weight ratio of the ionizable cationic lipid component to the nucleic acid is from about 5:1 to about 100:1, preferably from about 5:1 to about 50:1, preferably from about 5:1 to about 30:1, and more preferably from about 10:1 to about 20:1.

[0158] 9. The composition as described in Scheme 1 is characterized in that the lipid nanoparticle composition further includes a finished buffer, which contains a buffer and / or a cryoprotectant.

[0159] 10. The composition of claim 9, wherein the buffer is selected from acetate, formate, carbonate, phosphate, borate, succinate, gluconate, lactate, citrate, glycine, leucine, barbituric acid, phthalic acid, tromethamine (Tris), triethylamine, ammonium salts, or a combination thereof, such that the pH of the buffer is 7-8, or

[0160] The cryoprotectant is selected from substances such as sugars / polyols, polymers, surfactants, amino acids and salts, wherein the sugar can be selected from lactose, sucrose, trehalose, galactose and the like.

[0161] 11. The composition as described in Scheme 9 is characterized in that the finished buffer solution comprises: tromethamine, sodium acetate, and sucrose, and the pH value of the finished buffer solution is 7-8.

[0162] 12. The composition of claim 1, wherein the nucleic acid is selected from an mRNA comprising a nucleotide sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to the nucleotide sequence of any one of SEQ ID NOs: 1 to 6, preferably SEQ ID NO: 1, or an mRNA encoding a coronavirus antigen that comprises an amino acid that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of SEQ ID NOs: 7, or an mRNA comprising a nucleotide sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to the nucleotide sequence of any one of SEQ ID NOs: 8 to 26.

[0163] 13. The composition as described in Scheme 12 is characterized in that the composition includes lipid nanoparticles encapsulating nucleic acid, 20 mmol / L tromethamine, 10.7 mmol / L sodium acetate and 8.7% sucrose, pH 7.0-8.0; the mRNA concentration is 100 μg / ml; the lipid nanoparticles contain 50 mol% SM-102, 10 mol% DSPC, 38.5 mol% cholesterol and 1.5 mol% mPEG-DMG-2K, and the empty loading rate is not more than 10%.

[0164] 14. A method for preparing the lipid nanoparticle composition, comprising the following steps:

[0165] (1) dissolving the lipid component in an organic solvent to form an organic phase; (2) dissolving the nucleic acid in an acidic buffer to form an aqueous phase; (3) mixing the organic phase and the aqueous phase, and then encapsulating the nucleic acid with the lipid to form precursor lipid nanoparticles; (4) replacing the organic solvent-acidic buffer system containing the precursor lipid nanoparticles obtained in step (3) with a neutral buffer system in two stages to obtain finished lipid nanoparticles: the first stage is replaced with an acidic buffer or a neutral buffer; the second stage is replaced with a neutral buffer.

[0166] 15. The preparation method as described in Scheme 14 is characterized in that in the two-stage replacement process described in step (4), at the end of the first stage, the organic solvent content in the buffer system containing the precursor lipid nanoparticles is reduced to less than or equal to 5% (w / w), preferably less than 3% (w / w).

[0167] 16. The preparation method as described in Scheme 14 is characterized in that in the two-stage replacement process described in step (4), at the end of the first stage, the pH value of the buffer system containing the precursor lipid nanoparticles is lower than the pKa of the lipid nanoparticles by more than 0.5 units.

[0168] 17. The preparation method as described in Scheme 14 is characterized in that in the two-stage replacement process described in step (4), at the end of the second stage, the organic solvent content in the buffer system containing the finished lipid nanoparticles is reduced to less than 1% (w / w), preferably less than 0.1% (w / w).

[0169] 18. The preparation method as described in Scheme 14 is characterized in that in the two-stage replacement process described in step (4), at the end of the second stage, the pH value of the buffer system containing the finished lipid nanoparticles is more than 0.5 units higher than the pKa of the lipid nanoparticles.

[0170] 19. The preparation method as described in Scheme 14 is characterized in that the preparation method optionally includes step (5) concentration, dilution, sterile filtration, aseptic filling and a combination thereof.

[0171] 20. The preparation method as described in Scheme 14 is characterized in that the organic solvent in step (1) is selected from C1 to C4 low-carbon alcohols, preferably ethanol.

[0172] 21. The preparation method as described in Scheme 14 is characterized in that the total concentration of lipid components in the organic phase in step (1) is 10-15 mg / ml.

[0173] 22. The preparation method as described in Scheme 14 is characterized in that the concentration of nucleic acid in the aqueous phase in step (2) is 0.01-1 mg / ml, preferably 0.05-0.5 mg / ml, and preferably 0.1-0.2 mg / ml.

[0174] 23. The preparation method as described in Scheme 14 is characterized in that the acidic buffer in step (2) or step (4) contains a buffer, and the buffer is selected from acetate, formate, carbonate, phosphate, borate, succinate, gluconate, lactate, citric acid, glycine, leucine, barbituric acid, phthalic acid, tromethamine (Tris), triethylamine ammonium salt, sodium chloride, potassium chloride or a combination thereof, so that the pH value of the acidic buffer is less than the pKa of the lipid nanoparticles.

[0175] 24. The preparation method as described in Scheme 14 is characterized in that the acidic buffer solution in step (2) or step (4) also contains an osmotic pressure regulator, and the osmotic pressure regulator is selected from sodium chloride, potassium chloride, etc.

[0176] 25. The preparation method as described in Scheme 14 is characterized in that the pKa of the lipid nanoparticles is 6.0-7.0, and the pH value of the acidic buffer solution in step (2) or step (4) is less than the pKa of the lipid nanoparticles, such as 3.0-5.0, preferably 4.0-5.0.

[0177] 26. The preparation method as described in Scheme 14 is characterized in that the acidic buffer solution described in step (2) or step (4) contains citric acid and sodium chloride, preferably, contains 10-20 mM citric acid and 120-140 mM sodium chloride.

[0178] 27. The preparation method as described in Scheme 14 is characterized in that the volume ratio of the mixture of the organic phase and the aqueous phase in step (3) is 1:2-1:9, preferably 1:2-1:5, and preferably 1:3.

[0179] 28. The preparation method as described in Scheme 14 is characterized in that the replacement process in step (4) is selected from one or more of tangential flow filtration, membrane dialysis, column dialysis, and dilution.

[0180] 29. The preparation method as described in Scheme 14 is characterized in that the two-stage replacement process in step (4) can be repeated multiple times, that is, step (4) can be a process of increasing and decreasing the pH value alternately multiple times, and crossing the pKa of the lipid nanoparticles can reduce the particle empty loading rate.

[0181] 30. The preparation method as described in Scheme 14 is characterized in that the neutral buffer solution described in step (4) contains a buffer selected from acetate, formate, carbonate, phosphate, borate, succinate, gluconate, lactate, citric acid, glycine, leucine, barbituric acid, phthalic acid, tromethamine (Tris), triethylamine, ammonium salt, sucrose and combinations thereof, so that the pH value of the neutral buffer solution is greater than the pKa of the lipid nanoparticles.

[0182] 31. The preparation method as described in Scheme 14 is characterized in that the pKa of the lipid nanoparticles is 6.0-7.0, and the pH value of the neutral buffer solution described in step (4) is greater than the pKa of the lipid nanoparticles, such as 7.0-8.0. BRIEF DESCRIPTION OF THE DRAWINGS

[0183] FIG1 shows the structure of the linearized plasmid template of the T7 promoter in Preparation Example 1;

[0184] FIG2 shows a curve showing the change of fluorescence intensity with pH value when the pKa value of lipid nanoparticles containing SM-102 was determined by TNS method;

[0185] FIG3 shows the curves of particle size and PDI of lipid nanoparticles containing SM-102 as a function of pH value in the two-step dialysis process;

[0186] FIG4 shows a curve showing the change in particle size of different cationic lipid LNPs with dialysis times during buffer exchange;

[0187] FIG5 shows the curves of the PDI of different cationic lipid LNPs changing with dialysis times during the buffer exchange process;

[0188] FIG6 shows a curve showing the change of LNP particle size during reverse dialysis;

[0189] Figure 7 shows fluorescence nanoflow cytometry graphs of intermediates in the LNP preparation process according to Embodiment 1-1 after two-phase mixing (A), after dialysis against pH 4.0 buffer (B), and after dialysis against pH 7.6 buffer (C), wherein the abscissa SS-H represents the scattering signal peak height, the ordinate FITC-A represents the fluorescence signal peak area, P1 represents the proportion of loaded LNP, and P2 represents the proportion of unloaded LNP;

[0190] Figure 8 shows cryo-TEM images of intermediates in the LNP preparation process after two-phase mixing, dialysis against pH 4.0 buffer, and dialysis against pH 7.6 buffer according to Embodiment 1-1;

[0191] FIG9 shows a typical cryo-TEM image of the finished lipid nanoparticles of embodiment 1-1;

[0192] FIG10 shows a typical cryo-TEM image of the finished lipid nanoparticles of Comparative Scheme 1-1;

[0193] Figure 11 shows the pseudovirus neutralizing antibody activity of immune sera obtained after immunizing mice with the lipid nanoparticle compositions prepared by Embodiment 1-1 and Comparative Scheme 1-1;

[0194] FIG12 shows a comparison of the in vitro cell transfection efficacy of luciferase mRNA-LNPs prepared according to the methods of Embodiment 1-1 and Comparative Scheme 1-1;

[0195] FIG13 shows the tissue distribution results of lipid nanoparticles prepared according to the methods of Embodiment 1-1 and Comparative Embodiment 1-1 in mice after administration to mice. DETAILED DESCRIPTION

[0196] In order to further understand the present invention, the specific embodiments of the present invention are described in detail below in conjunction with examples. However, it should be understood that the purpose of these descriptions is only to further illustrate the features and advantages of the present invention and does not constitute any limitation of the present invention.

[0197] Preparation Example 1 Preparation of mRNA

[0198] An exemplary method for preparing mRNA used in this application is as follows:

[0199] 1. According to the instructions of the IVT kit (E131, Novoprotein), the IVT reaction system was prepared by mixing 10× Transcription Buffer, ATP, GTP, CTP, 1-N-Me-Pseudo UTP (Cat. No. WA0992, Zhaowei Technology), 5' cap analog m7G(5')ppp(5')(2'OMeA)pG (Cat. No. GAGNH23C2L1B, Zhaowei Technology), water for injection, linearized plasmid template of T7 promoter (customized by GenScript Biotechnology Co., Ltd., structure see Figure 1), and Enzyme Mix; the sequences used are as follows:

[0200] 2. The mixed reaction system was placed at 37°C for 40 minutes;

[0201] 3. Add the corresponding proportion of DNase I to terminate the reaction.

[0202] After in vitro synthesis, S protein mRNA was isolated and purified by hydrophobic chromatography and ultrafiltration to obtain high-purity mRNA (>95%). The experimental results showed that the above steps produced highly pure mRNA, which can be used in subsequent experiments. Note: Internal standard (25 nt, Agilent, RNA 6000 Nano Kit (reorder no. 5067-1511)).

[0203] Example 1 Preparation of lipid nanoparticles by two-step dialysis process

[0204] This example describes a method for preparing low-load lipid nanoparticles according to the present invention, wherein the precursor lipid nanoparticles are dialyzed in a pH 4.0 buffer and a pH 7.6 buffer in two steps to obtain the finished lipid nanoparticles. The specific preparation method is as follows:

[0205] 1. Preparation of Precursor Lipid Nanoparticles

[0206] 1.1 Lipid phase preparation: Accurately weigh the four lipids and dissolve them in anhydrous ethanol at a molar ratio of 50% SM-102: mPEG-DMG-2K: DSPC: cholesterol of 1.5%: 10%: 38.5% to obtain a lipid phase with a total lipid concentration of 12 mg / ml.

[0207] 1.2 Preparation of aqueous phase: Dilute the mRNA stock solution obtained in Preparation Example 1 with 10 mM citric acid-130 mM sodium chloride buffer, pH 4.0, to obtain an aqueous phase with an mRNA concentration of 0.18 mg / ml;

[0208] 1.3 Mixing: The lipid phase and aqueous phase were transported using a horizontal flow pump and mixed in a microchannel mixer at a volume ratio of 1:3. The lipids encapsulated the mRNA to form a precursor lipid nanoparticle suspension.

[0209] 2. Preparation of Finished Lipid Nanoparticles

[0210] 2.1 Dialysis with pH 4.0 buffer: Take the precursor lipid nanoparticle suspension and dialyze it 1 to 5 times with 10 mM citric acid-130 mM sodium chloride buffer at pH 4.0 as the first stage dialysate by tangential flow filtration (TFF) to reduce the ethanol content in the system and obtain the pH 4.0 buffer dialyzed solution;

[0211] 2.2 Dialysis in pH 7.6 buffer: After dialyzing the drug solution in pH 4.0 buffer, use 20 mM Tris-10.7 mM NaOAc-8.7% sucrose solution at pH 7.6 as the second stage dialysate. Use tangential flow filtration (TFF) to dialyze the solution 3 to 6 times by equal volume. During the rising pH value, the particles fuse to form stable finished lipid nanoparticles.

[0212] In this method, during the first stage of dialysis using a pH 4.0 buffer, the system pH is maintained below the pKa of the lipid nanoparticles, and the ethanol content is gradually reduced to a certain level, ensuring that the ethanol content in the system is low when the particles fuse in the second stage. During the second stage of dialysis using a pH 7.6 buffer, when the system pH rises to near the pKa of the lipid nanoparticles, the particles begin to fuse, and the low ethanol content allows for more complete particle fusion. When the system pH exceeds the pKa of the lipid nanoparticles, the particle fusion is complete, forming thermodynamically stable finished lipid nanoparticles.

[0213] Some specific implementation plans of Example 1 are shown in Table 1.

[0214] Table 1 Specific implementation plan of Example 1

[0215] Comparative Example 1 Preparation of lipid nanoparticles by one-step dialysis process

[0216] This comparative example describes a conventional method for preparing lipid nanoparticles, wherein the precursor lipid nanoparticles are dialyzed in a pH 7.6 buffer solution in one step to obtain the finished lipid nanoparticles. The specific preparation method is:

[0217] 1. Preparation of precursor lipid nanoparticles: The method is the same as Example 1.

[0218] 2. Preparation of finished lipid nanoparticles: Take the precursor lipid nanoparticle suspension and use 20mM Tris-10.7mM NaOAc-8.7% sucrose solution at pH 7.6 or a higher concentration buffer as the dialysate. Use tangential flow filtration (TFF) to dialyze the suspension 5 to 8 times by equal volume. During the pH increase, the particles fuse to form finished lipid nanoparticles.

[0219] In this method, during the one-step dialysis process in pH 7.6 buffer, when the pH value of the system rises to near the pKa of the lipid nanoparticles, the particles begin to fuse. The ethanol content is high, and the particle fusion is insufficient, forming thermodynamically unstable finished lipid nanoparticles.

[0220] Some specific implementation plans of Comparative Example 1 are shown in Table 2.

[0221] Table 2 Specific implementation plan of Comparative Example 1

[0222] Example 2 Preparation of lipid nanoparticles by a two-step process of dilution followed by dialysis

[0223] This example describes an alternative method for preparing the low-load lipid nanoparticles of the present invention, wherein the precursor lipid nanoparticles are diluted with pH 4.0 buffer and dialyzed against pH 7.6 buffer to obtain the finished lipid nanoparticles. The specific preparation method is as follows:

[0224] 1. Preparation of precursor lipid nanoparticles: The method is the same as Example 1.

[0225] 2. Preparation of Finished Lipid Nanoparticles

[0226] 2.1 Dilution with pH 4.0 buffer: Take the precursor lipid nanoparticle suspension and dilute it 10-fold with 10 mM citric acid-130 mM sodium chloride buffer at pH 4.0. Reduce the ethanol content in the system without increasing the pH value to obtain a solution diluted with pH 4.0 buffer;

[0227] 2.2 Dialysis in pH 7.6 buffer: The drug solution diluted with pH 4.0 buffer was concentrated 10-fold using tangential flow filtration (TFF). The solution was then dialyzed 4-6 times with equal volumes of 20 mM Tris-10.7 mM NaOAc-8.7% sucrose solution at pH 7.6 as the dialysate. As the pH value increased, the particles fused to form stable finished lipid nanoparticles.

[0228] In this method, after dilution with a pH 4.0 buffer in the first stage, the system pH is lower than the pKa of the lipid nanoparticles, and the ethanol content is reduced to a certain level, ensuring that the ethanol content in the system is low when the particles fuse in the second stage. During the second stage of dialysis with a pH 7.6 buffer, when the system pH rises to near the pKa of the lipid nanoparticles, the particles begin to fuse, and the low ethanol content allows for more complete particle fusion. When the system pH exceeds the pKa of the lipid nanoparticles, the particle fusion is complete, forming thermodynamically stable finished lipid nanoparticles.

[0229] Some specific implementation plans of Example 2 are shown in Table 3.

[0230] Table 3 Specific implementation plan of Example 2

[0231] Comparative Example 2 Preparation of lipid nanoparticles by a two-step process of dilution followed by dialysis

[0232] This comparative example describes another conventional method for preparing lipid nanoparticles, wherein the precursor lipid nanoparticles are diluted with a pH 7.6 buffer and dialyzed to obtain the finished lipid nanoparticles. The specific preparation method is:

[0233] 1. Preparation of precursor lipid nanoparticles: The method is the same as Example 1.

[0234] 2. Preparation of Finished Lipid Nanoparticles

[0235] 2.1 Dilution with pH 7.6 buffer: Take the precursor lipid nanoparticle suspension and dilute it 3-fold with 20 mM Tris-10.7 mM NaOAc-8.7% sucrose solution at pH 7.6. The ethanol content decreases while the pH value of the system increases, and the drug solution diluted with pH 7.6 buffer is obtained;

[0236] 2.2 Dialysis in pH 7.6 buffer: The diluted drug solution was concentrated 3 times using tangential flow filtration (TFF), and then dialyzed 4 to 6 times with equal volumes of 20 mM Tris-10.7 mM NaOAc-8.7% sucrose solution at pH 7.6 as the dialysate. During the rising pH value, the particles fused to form finished lipid nanoparticles.

[0237] In this method, after the dilution of pH 7.6 buffer in the first stage, the pH value of the system increases; during the dialysis of pH 7.6 buffer in the second stage, the pH value of the system rapidly increases to near the pKa of the lipid nanoparticles, the particles begin to fuse, the ethanol content is high, the particles do not fuse sufficiently, and thermodynamically unstable finished lipid nanoparticles are formed.

[0238] The specific implementation plan of Comparative Example 2 is shown in Table 4.

[0239] Table 4 Comparative Example 2 Specific Implementation Plan

[0240] Example 3 Preparation of lipid nanoparticles by one-step dialysis process (improving the buffering capacity of acidic buffer)

[0241] This example describes a method for preparing low-load lipid nanoparticles according to the present invention, wherein the precursor lipid nanoparticles are dialyzed in a pH 7.6 buffer in a single step to obtain the finished lipid nanoparticles. The specific preparation method is as follows:

[0242] 1. Preparation of Precursor Lipid Nanoparticles

[0243] 1.1 Preparation of lipid phase: the method is the same as that in Example 1;

[0244] 1.2 Preparation of aqueous phase: Dilute the mRNA stock solution with 20 mM citric acid-130 mM sodium chloride buffer, pH 4.0, to obtain an aqueous phase with an mRNA concentration of 0.18 mg / ml;

[0245] 1.3 Mixing: The method is the same as in Example 1.

[0246] 2. Preparation of finished lipid nanoparticles: The method is the same as that of Comparative Example 1.

[0247] In this method, a higher concentration of citric acid buffer is used when preparing precursor lipid nanoparticles, reducing the rate of increase in the system pH during the one-step dialysis buffer replacement process. This reduces the ethanol content in the system to an acceptable level by the time the particles fuse, allowing the particles to fully fuse and form thermodynamically stable finished lipid nanoparticles. The one-step dialysis process of this embodiment can be divided into two stages. In the first stage, the system pH is lower than the pKa of the lipid nanoparticles, and the ethanol content is reduced to a certain level, ensuring that the ethanol content in the system is low when the particles fuse in the second stage. In the second stage, when the system pH rises to near the pKa of the lipid nanoparticles, the particles begin to fuse, the ethanol content is low, and the particles fuse more fully. When the system pH exceeds the pKa of the lipid nanoparticles, the particle fusion is complete, forming thermodynamically stable finished lipid nanoparticles.

[0248] Some specific implementation plans of Example 3 are shown in Table 5.

[0249] Table 5 Specific implementation plan of Example 3

[0250] Example 4 Preparation of Precursor Lipid Nanoparticles by Post-Loading Process

[0251] This example describes an alternative method for preparing the precursor lipid nanoparticles of the present invention. Unlike the standard preparation process of Example 1, which directly mixes the lipid phase with the aqueous phase containing nucleic acids, the post-loading process first mixes the lipid phase with an acidic buffer solution that does not contain nucleic acids to form blank lipid nanoparticles, which are then mixed with the aqueous phase containing nucleic acids to form lipid-encapsulated nucleic acids. The specific preparation method is as follows:

[0252] 1.1 Lipid phase preparation: Accurately weigh the four lipids and dissolve them in anhydrous ethanol at a molar ratio of 50% SM-102: mPEG-DMG-2K: DSPC: cholesterol of 1.5%: 10%: 38.5% to obtain a lipid phase with a total lipid concentration of 12 mg / ml.

[0253] 1.2 Preparation of blank lipid nanoparticles: The lipid phase and 10 mM citric acid-130 mM sodium chloride buffer (pH 4.0) were delivered using a horizontal flow pump and mixed in a microchannel mixer at a volume ratio of 1:3 to form a blank lipid nanoparticle suspension;

[0254] 1.3 Preparation of aqueous phase: Dilute the mRNA stock solution obtained in Preparation Example 1 with 10 mM citric acid-130 mM sodium chloride buffer, pH 4.0, to obtain an aqueous phase with an mRNA concentration of 0.18 mg / ml;

[0255] 1.4 Preparation of precursor lipid nanoparticles: A blank lipid nanoparticle suspension and an aqueous phase were delivered using a horizontal flow pump and mixed in a microchannel mixer at a volume ratio of 4:3. The lipid-encapsulated mRNA formed a precursor lipid nanoparticle suspension.

[0256] Example 5 Study on the relationship between particle fusion pH and lipid nanoparticle pKa

[0257] The lipid nanoparticle fusion process is closely related to the charge of the LNP containing ionizable cationic lipids. The charge ratio of ionizable cationic lipids at different pH values ​​conforms to the Henderson-Hasselbalch equation:

[0258] Among them [BH + ] is the concentration of positively charged ionizable cationic lipids, and [B] is the concentration of neutral ionizable cationic lipids. This Example uses the ionizable cationic lipid SM-102 as an example to investigate the relationship between the pH values ​​at which particle fusion begins and ends during buffer exchange and the pKa of the LNP containing the ionizable cationic lipid, using changes in particle size. Furthermore, a comparison of particle size changes during buffer exchange for LNPs containing the cationic lipid DOTAP, the ionizable cationic lipids SM-102, and Dlin-MC3-DMA was performed to reveal whether different types of cationic lipids affect the particle fusion process.

[0259] 1. pKa Determination of LNPs Containing Ionizable Cationic Lipids

[0260] The pKa of LNPs containing ionizable cationic lipids was determined using the commonly used 6-(p-toluidinyl)-2-sulfonic acid sodium salt (TNS) fluorescent probe reported in the literature. TNS is non-fluorescent in aqueous solution, but exhibits strong fluorescence upon binding to cationic lipids and entering a hydrophobic environment. As the pH value decreases, the interaction between the negatively charged TNS and the positively charged ionizable cationic lipids increases, leading to an increase in the fluorescence signal. The fluorescence signal intensity-pH curve was fitted using the Boltzmann function, and the pH value at the peak after taking the derivative of the fitting result was the pKa of the LNP containing ionizable cationic lipids. The specific determination method is as follows:

[0261] 1.1 Preparation of SM-102 lipid nanoparticles: The preparation method is the same as Example 1.

[0262] 1.2 Determination of the pKa of SM-102 lipid nanoparticles

[0263] Add 1 ml of buffer with different pH gradients (citrate, phosphate, or borate buffer) to a centrifuge tube, and add 50 μl of SM-102 lipid nanoparticle dispersion to prepare sample solutions with different pH gradients. Take 200 μl of sample solutions with different pH gradients and add them to a 96-well plate. Add 30 μl of the prepared TNS-DMSO Reagent (300 μM) to each well and place in the dark for 5 minutes. Place the 96-well plate in a microplate reader, select the fluorescence mode, set the excitation wavelength to 321 nm, and the emission wavelength to 445 nm. Use the Boltzmann function to fit the fluorescence signal intensity-pH value curve. After derivation of the fitting result, the pH value at the peak (peak center) is 6.52, which is the pKa value of the SM-102 lipid nanoparticles. The fitting curve is shown in Figure 2.

[0264] 2. Relationship between particle fusion pH and the pKa of ionizable cationic lipids

[0265] Precursor lipid nanoparticles were prepared according to the method described in Example 1, and then finished lipid nanoparticles were prepared using a two-step dialysis process. During the pH increase, the particle size was used as an indicator to illustrate the fusion process of ionizable cationic lipid particles and the relationship between the pH value at which fusion occurs and the pKa of the ionizable cationic lipid LNP.

[0266] The two-step dialysis process was as follows: SM-102 precursor lipid nanoparticles were dialyzed three times against an equal volume of 10 mM citric acid-130 mM sodium chloride buffer (pH 4.0), then dialyzed against a 20 mM Tris-10.7 mM NaOAc-8.7% sucrose solution (pH 7.6). As the pH increased, samples were taken at pH 4.0, 4.5, 5.0, 5.5, 6.0, 6.2, 6.8, 7.2, and 7.4 to measure particle size and PDI. The dialyzed SM-102 finished lipid nanoparticles were adjusted to pH 8.0 and 8.5 with sodium hydroxide solution, and samples were taken to measure particle size and PDI. The results are shown in Table 6 and Figure 3.

[0267] Table 6 Changes in particle size and PDI of SM-102 lipid nanoparticles with pH value

[0268] During the dialysis process, when the pH value rose to 6.0, the particle size did not change significantly, and the particles had not yet begun to fuse. When the pH value rose to near the pKa of SM-102 (6.2 and 6.8), the particle size and PDI increased significantly, and the particles were fusing. When the pH value rose to 7.2 and above, the PDI decreased, and the particle size and PDI remained at a stable level, and the particles completed fusion. Therefore, in the two-stage replacement process, the purpose of the first stage is to reduce the organic solvent concentration in the system, and the pH should be maintained at ≤pKa-0.5. At this time, the particles have not yet undergone significant fusion. The purpose of the second stage is to fuse the particles to form finished lipid nanoparticles. The process endpoint pH should be ≥pKa+0.5. At this time, the particles have completed fusion and reached a steady state.

[0269] 3. Changes in different cationic lipid LNP particles during buffer exchange

[0270] Precursor lipid nanoparticles were prepared using the ionizable cationic lipid SM-102, Dlin-MC3-DMA, and the permanently charged cationic lipid DOTAP according to the method described in Example 1. Finished lipid nanoparticles were then prepared using a two-step dialysis process. The particle fusion process was studied using particle size as an indicator during the pH increase.

[0271] Precursor lipid nanoparticles were prepared using the cationic lipid DOTAP, the ionizable cationic lipid SM-102, or Dlin-MC3-DMA according to the method described in Example 1. Ethanol was removed by dialysis three times against an equal volume of 10 mM citric acid-130 mM sodium chloride buffer (pH 4.0). The particles were then dialyzed against a 20 mM Tris-10.7 mM NaOAc-8.7% sucrose solution (pH 7.6). Samples were taken during the rising pH period to determine ethanol content, particle size, and PDI. The results are shown in Table 7 and Figures 4-5.

[0272] Table 7 Changes in particle size and PDI during buffer exchange of different cationic lipid LNPs

[0273] From the changes in particle size and PDI during the buffer system replacement process in the above table, it can be seen that: (1) Lipid nanoparticles containing ionizable cationic lipids SM-102 and Dlin-MC3-DMA fuse at pH 6.36 and 6.40, respectively, and the particle size and PDI increase; then they complete fusion at pH 7.29 and 7.30, respectively, with a significant increase in particle size and a significant decrease in PDI; after the particle fusion is completed, the particle size and PDI remain at a stable level; (2) Lipid nanoparticles containing cationic lipid DOTAP are always charged within the process pH range, and the particle size and PDI continue to increase slowly. There is no particle fusion process caused by changes in charge during the buffer system replacement process. These results indicate that there is no particle fusion process caused by changes in charge during the buffer system replacement process for permanently charged cationic lipid LNPs, while there is a common particle fusion process for ionizable cationic lipid LNPs, and the fusion occurs near the pH value reaching pKa.

[0274] Example 6 Summary of physicochemical properties of lipid nanoparticles from different examples and comparative examples

[0275] 1. Encapsulation efficiency determination method: use Fluorescence kit was used to determine the encapsulation efficiency of nucleic acid in the finished lipid nanoparticles. The sample was diluted with TE buffer and added to a black polystyrene 96-well plate. TE buffer or the same volume of Triton X-100 was added. After incubation, the sample was diluted with TE. Fluorescence reagent, the fluorescence intensity is measured at an excitation wavelength of 480nm and an emission wavelength of 520nm. The ratio of the fluorescence signal of the TE diluted sample to the Trion X-100 damaged sample is the percentage of free mRNA.

[0276] 2. Particle size determination method: The particle size and polydispersity index (PDI) of lipid nanoparticles were determined using a Malvern Zetasizer Nano ZS laser nanoparticle size analyzer.

[0277] 3. Comparison of Particle Physicochemical Properties: During the buffer exchange process, the degree of particle fusion is affected by the organic solvent content during fusion, which in turn affects key physicochemical properties of the finished lipid nanoparticles, such as particle size, PDI, and encapsulation efficiency, as well as storage stability. Key physicochemical properties and residual organic solvent before and after fusion of the particles from different Examples and Comparative Examples during the buffer exchange process were statistically compared. The results of this comparison of key physicochemical properties of the particles before and after fusion are shown in Table 8.

[0278] Table 8 Comparison of key physical and chemical properties of particles before and after fusion in different embodiments and comparative examples

[0279] As can be seen from the table above, compared with the method of the comparative solution, the preparation method of the present invention reduces the ethanol content to a lower level (<5%) before particle fusion, thereby making the particles fusion more complete, as shown by the larger particle size after fusion.

[0280] Example 7 Effect of ethanol content on particle fusion

[0281] Precursor lipid nanoparticles were prepared according to the method described in Example 1. 0.5 ml of the precursor lipid nanoparticle suspension was injected into a 5 ml G50 dextran gel column pre-equilibrated with a 20 mM Tris-10.7 mM NaOAc-8.7% sucrose solution at pH 7.6 containing different ethanol contents. Elution was then performed using the corresponding equilibration buffer. When the eluate turned milky white, the sample was collected. The pH value and particle size of the finished lipid nanoparticles prepared by dialysis on the dextran gel column were determined using the collected sample. The effect of ethanol content on particle fusion during dialysis on the dextran gel column was investigated. The results are shown in Table 9.

[0282] Table 9 Effect of ethanol content on particle fusion

[0283] When the particles fuse, if the ethanol content is ≤5%, the particle size growth rate is similar, the particle size after dialysis is above 105nm, and the particles are fully fused; if the ethanol content is ≥10%, the particle size growth rate is smaller, the particle size after dialysis is below 90nm, and the particles are not fully fused.

[0284] Example 8 Reverse Dialysis

[0285] The conclusion that stable particles and metastable particles exist in the fusion process was further confirmed by reverse dialysis. The specific implementation method of reverse dialysis is as follows: according to the method described in Example 1, precursor lipid nanoparticles are first prepared; the precursor lipid nanoparticle suspension is taken and dialyzed 5 times with an equal volume of 20mM Tris-10.7mM NaOAc-8.7% sucrose solution at pH 7.6 using a tangential flow filtration process, and then reverse dialyzed 3 times with an equal volume of 10mM citric acid-130mM sodium chloride buffer at pH 4.0, and finally dialyzed 3 times with an equal volume of 20mM Tris-10.7mM NaOAc-8.7% sucrose solution at pH 7.6.

[0286] During the reverse dialysis process for preparing the finished lipid nanoparticles, the system undergoes a change from acidic → neutral → acidic → neutral. The first process from pH 4.0 to pH 7.6 is consistent with the one-step dialysis process for preparing the finished lipid nanoparticles in Comparative Example 1. The first stage ends with 1 equal volume dialysis. The pH of the system is below the pKa of the lipid nanoparticles containing ionizable cationic lipids, and the ethanol content is 8%, which is higher than the acceptable standard. The second stage ends with 2 equal volume dialysis or more. The pH of the system rises to above the pKa of the lipid nanoparticles containing ionizable cationic lipids. During the pH increase, the particles fuse to form finished lipid nanoparticles. Due to the high ethanol content in the system, the fusion between the particles is insufficient and a steady state is not reached. After 5 times of dialysis to remove ethanol, the particle size obtained is 80 nm. Reverse dialysis from pH 7.6 to pH 4.0, the unloaded LNP and the unstable LNP fuse again to reach a steady state, and the resulting particle size is 110 nm. The second time from pH 4.0 to pH 7.6, the particle size obtained is 117 nm, which is basically the same as after reverse dialysis. The changes in particle size and PDI during the process are shown in Table 10 and Figure 6.

[0287] Table 10 Changes in particle size and PDI during reverse dialysis

[0288] The results show that when particles fuse, the high ethanol content of the system (>5%) leads to insufficient particle fusion. The obtained metastable particles further fuse to obtain stable particles at a low ethanol content (<0.1%), suggesting that metastable particles may undergo significant changes in physical and chemical properties (particle size, etc.) during storage.

[0289] Example 9: Detection of Nucleic Acid Loading Ratio by Fluorescence Nanoflow Cytometry

[0290] Fluorescence nanoflow cytometry was used to determine the ratio of loaded LNP to unloaded LNP, thereby conducting a comparative study on the particle fusion during the process and the ratio of loaded LNP to unloaded LNP in products prepared by different processes.

[0291] The basic principle of fluorescent nanoflow cytometry for determining nucleic acid loading ratios is as follows: after adding a transmembrane nucleic acid dye to the sample, the dye penetrates the LNP membrane and binds to the internal mRNA, generating fluorescence. The ratio of loaded to unloaded LNPs in the sample is calculated using the fluorescence signal and the scattering signal. The specific experimental method is to take the sample to be tested, add a ribozyme to incubate to remove free mRNA, add a nucleic acid dye to incubate, and then use a nanoflow cytometer to measure the scattered light signal of a single LNP. The dye fluorescence labeling can be used to quickly distinguish between unloaded LNPs and nucleic acid-loaded LNPs, thereby calculating the ratio of loaded to unloaded LNPs.

[0292] Fluorescence nanoflow cytometry was used to measure the changes in the ratio of intermediate-loaded LNPs to empty LNPs during the LNP preparation process of Implementation 1-1. The results are shown in Table 11 and Figure 7. After mixing the lipid and aqueous phases and dialysis against a pH 4.0 buffer, the LNP-loaded ratio was approximately 20%. After dialysis against a pH 7.6 buffer, due to the steady-state particle fusion, there were essentially no empty LNPs in the system, and the proportion of mRNA-loaded particles reached over 90%.

[0293] Table 11 Changes in the ratio of loaded LNP to unloaded LNP during the LNP preparation process (Implementation Plan 1-1)

[0294] Fluorescence nanoflow cytometry was used to test the ratio of LNP-loaded and empty LNP-loaded finished lipid nanoparticles obtained from different examples and comparative examples. The results are shown in Table 12. The empty LNP ratio of the examples was less than 10%, indicating sufficient particle fusion, low empty rate, and steady state.

[0295] Table 12 Ratio of finished products loaded with LNP and empty LNP in different embodiments and comparative examples

[0296] Example 10 Cryo-TEM Characterization

[0297] Cryo-transmission electron microscopy (Cryo-TEM) was used to characterize the morphology of lipid nanoparticles, and the changes in particle morphology during the process and the morphology of products prepared by different preparation processes were compared.

[0298] A cryo-TEM image of an intermediate during the LNP preparation process of Embodiment 1-1 is shown in Figure 8. After mixing the lipid and aqueous phases and dialysis against pH 4.0 buffer, small lipid nanoparticles are present in the system. After dialysis against pH 7.6 buffer, the particles fuse to form large, uniform lipid nanoparticles. Cryo-TEM results indicate that particles fuse during the LNP preparation process. This result is consistent with the particle size and fluorescence nanofluidics results.

[0299] The cryo-TEM image of the finished lipid nanoparticles obtained by Implementation Scheme 1-1 is shown in FIG9 , and the particles are uniform in size and consistent in morphology; the cryo-TEM image of the finished lipid nanoparticles obtained by Comparative Scheme 1-1 is shown in FIG10 , and the particles have different morphologies, with a large number of pre-fused LNPs or empty LNPs. Such particles are thermodynamically unstable systems, and the physical and chemical properties of the particles may change during storage.

[0300] Example 11 Preparation of lipid nanoparticles encapsulating different types of nucleic acids

[0301] Lipid nanoparticles can be used to deliver various genetic materials, including siRNA, pDNA, and mRNA. siRNA (standard siRNA, Genetron Health) and pDNA (pVAX.1, GenScript Biotech) lipid nanoparticles were prepared using the method of Embodiment 1-1 of the present invention. The physical and chemical properties and nucleic acid loading ratios of the resulting products are shown in Table 13. As shown in the table, the products exhibited uniform particle size, high encapsulation efficiency, and low empty load rate.

[0302] Table 13 Physicochemical properties of different nucleic acid LNP products and nucleic acid loading ratios

[0303] The above-mentioned siRNA (patisiran sodium, MedChemExpress) sequence: RNA, (SEQ ID NO: 28, AUGGAA-Um-ACUCUUGGU-Um-AC-dT-dT), combined with RNA (SEQ ID NO: 29, G-Um-A-ACm-Cm-AAGAG-Um-A-Um-Um-Cm-Cm-A-Um-dT-dT) (1:1) sodium salt, wherein m represents 2'-OMe modification and dT represents thymidine deoxyribonucleotide.

[0304] The above-mentioned pDNA (pVAX.1) was obtained from Invitrogen TM , item number: V26020.

[0305] The method of embodiment 1-1 of the present invention was adopted, and the mRNA stock solution obtained in Preparation Example 1 was replaced with mRNA represented by other sequences of the present invention (SEQ ID NOs: 2-7, or mRNA represented by SEQ ID NOs: 8-26). The remaining operations were the same as those in embodiment 1-1, and products with uniform particle size, high encapsulation efficiency, and low empty rate were obtained. Ideal properties.

[0306] Example 12 Study on the Storage Stability of Intermediates in the Preparation of Lipid Nanoparticles

[0307] The intermediates in the preparation process of Implementation Option 1-1 were placed at 2-8°C for 2 months and then their particle size was tested. The results showed that the particles that had been completely fused (after dialysis with pH 7.6 buffer) had good stability, and the average particle size and PDI did not change significantly. However, the particles that were not completely fused (after mixing and dialysis with pH 7.6 buffer) had a significant increase in particle size and a larger PDI. The results are shown in Table 14.

[0308] Table 14 Storage stability of intermediates in the LNP preparation process

[0309] Example 13 Study on freeze-thaw stability of mRNA-LNP

[0310] During storage, transportation, and use, lipid nanoparticles produced using different preparation processes exhibited varying stability. For cryopreserved mRNA-LNPs, changes in the physicochemical properties of the finished lipid nanoparticles produced using the preparation processes of Implementation 1-1 and Comparative Scheme 1-1 were investigated following repeated freeze-thaw cycles (-20°C ± 5°C / room temperature). The results are shown in Table 15.

[0311] Table 15 mRNA-LNP freeze-thaw stability

[0312] After 30 freeze-thaw cycles, the mRNA-LNP prepared in Implementation Scheme 1-1 had a significantly smaller increase in particle size and PDI than those in Comparative Scheme 1-1, indicating that the lipid nanoparticles prepared in Implementation Scheme 1-1 had better freeze-thaw stability.

[0313] Example 14 Study on the stability of mRNA-LNP during freezing, refrigeration and room temperature

[0314] The lipid nanoparticle composition (mRNA-LNP) prepared in Example 1-1 was stored under frozen (-20°C ± 5°C), refrigerated (5°C ± 3°C), and room temperature (25°C ± 2°C). Samples were taken at different time points to analyze particle size, PDI, mRNA purity, and biological activity. Stability results are shown in Table 16.

[0315] mRNA purity detection method: mRNA was extracted and purified using the PureLink RNA Mini Kit (Invitrogen), concentrated to a concentration of 200 ng / μl using a 30KD ultrafiltration centrifuge tube (Merck), and analyzed and confirmed using a Nanodrop UV spectrophotometer (Thermo). The purity of the mRNA was evaluated using an Agilent 2100 bioanalyzer.

[0316] Biological activity detection method: Healthy, well-grown BALB / c mice aged 6-8 weeks were selected, and randomly divided into groups after weight division, with 10 mice in each group, half of which were male and half were female. Each animal was given a dose of 5 μg each time, and immunized twice with an interval of 7 days. Serum was collected 7 days after the last dose, and the anti-S protein binding antibody titer in individual mouse serum samples was determined by ELISA, and then the geometric mean of the antibody titer of all tested mice was calculated.

[0317] Table 16 Storage stability of mRNA-LNP during freezing, refrigeration and room temperature

[0318] The results showed that the lipid nanoparticle composition (mRNA-LNP) did not undergo significant changes in its physicochemical properties and biological activity after being stored in a refrigerator (5°C±3°C) for 6 months, at room temperature (25°C±2°C) for 14 days, and in a frozen state (-20°C±5°C) for 12 months. Compared with similar products, it has better thermal stability.

[0319] Example 15 Pseudovirus Neutralizing Antibody Efficacy Detection

[0320] The lipid nanoparticles prepared by Implementation 1-1 and Comparative Scheme 1-1 were used to immunize BALB / c mice (6-8 weeks old, Beijing Weitonglihua Experimental Animal Technology Co., Ltd.) by intramuscular injection (5 / group, female), respectively, using two immunization procedures: (1) 2 injections with an interval of 7 days, serum was collected 14 days after the last dose, and the dosage was 10 μg; (2) 2 injections with an interval of 21 days, serum was collected 7 days after the last dose, and the dosage was 3 μg. After immunization, the mouse serum was collected and diluted with DMEM complete medium (Hyclone, containing 1% double antibody, 10% FBS, 1% non-essential amino acids, 1% HEPES), initially diluted 30 times, and then diluted 3 times continuously, and then mixed with 650TCID 50 SARS-CoV-2WT and BA.4 / 5 pseudovirus strains (Zhongke Guobang (Beijing) Testing Co., Ltd.) were co-incubated at 37°C for 1 h, and then 2× 10 4 Vero cells were cultured for 20-28 hours, the supernatant was discarded, and luciferase detection reagent (PerkinElmer) was added. The fluorescence value was read, and the 50% neutralizing antibody titer was calculated according to the Reed-Muench method. The results are shown in Figure 11. The results showed that for both immunization procedures, the neutralizing activity of the immune serum of embodiment 1-1 against both WT and BA.4 / 5 pseudoviruses was superior to that of the control 1-1.

[0321] Example 16 In vitro cell transfection efficacy detection

[0322] Using the present invention embodiment 1-1 and comparative scheme 1-1 method, SEQ ID NO:1 mRNA is replaced with the RNA sequence encoding luciferase (SEQ ID NO:27), and luciferase mRNA-LNP is prepared. Luciferase mRNA-LNP is incubated with HEK293T cells (ATCC), and 4 groups are set up, with a dosage of 50ng mRNA / hole, 100ng mRNA / hole, 200ng mRNA / hole, 400ng mRNA / hole (96-well plate), and luciferase detection reagent (Promega) is added after incubation for 24h to quantitatively detect the expression of luciferase (n=3). Data analysis uses a two-tailed unpaired t-test, * represents P < 0.05, ** represents P < 0.01, *** represents P < 0.001, ns represents no significant difference, and the results are shown in Figure 12. The results showed that the in vitro cell transfection efficiency of the luciferase mRNA-LNP prepared by the method of Implementation Scheme 1-1 was significantly better than that of the luciferase mRNA-LNP prepared by the method of Comparative Scheme 1-1.

[0323] Example 17 Animal tissue distribution test

[0324] C57BL / 6J mice (6-8 weeks old, Beijing Weitonglihua Experimental Animal Technology Co., Ltd.) were injected intramuscularly with 5 μg of lipid nanoparticles prepared by Implementation Scheme 1-1 and Comparative Scheme 1-1 (6 mice / group, half male and half female). Whole blood was collected from the mice 2h, 24h and 96h after administration (orbital blood, EDTA anticoagulation), and the mouse heart and local muscle tissue were obtained after perfusion with normal saline. RNA was extracted using the PureLinkRNA Mini Kit (Thermo Fisher Scientific), and the RNA concentration was determined by ultraviolet spectrophotometry (instrument Nanodrop, Thermo Scientific). Secondly, PrimeScript TMRNA was reverse transcribed into cDNA using the RT Master Mix Kit (TaKaRa). Taq Pro HS Universal U+Probe Master Mix (Vazyme) was added and primers PRD-F6 (SEQ ID NO: 30, AGCGTGCTCTATAACTCGGC), PRD-R6 (SEQ ID NO: 31, TCGGACCTCATCGCCTCTAA), and PRD-P6 (SEQ ID NO: 32, ACGGCGTGAGCCCCACAAAG) were used for quantitative PCR on a LightCycler 480 real-time PCR instrument to quantify mRNA levels in blood and tissues. Data were analyzed using a two-tailed unpaired t-test. * indicates P < 0.05, ** indicates P < 0.01, and *** indicates P < 0.001. ns indicates no significant difference. The results are shown in Figure 12. The AUC (area under the curve) results 96 hours after administration showed that the sample prepared using Embodiment 1-1 had lower mRNA distribution levels in the heart and blood, which reduced the possibility of myocarditis and systemic adverse reactions.

[0325] The relevant sequences involved in this application are as follows:

[0326] SEQ ID NO: 1

[0327] SEQ ID NO:2

[0328] SEQ ID NO:3

[0329] SEQ ID NO:4

[0330] SEQ ID NO:5

[0331] SEQ ID NO:6

[0332] SEQ ID NO:7

[0333] (The underlined mutation sites are relative to the WT strain)

[0334] SEQ ID NO.8 (SF-1-BA.5 BA.5S protein native sequence)

[0335] SEQ ID NO.9 (SF-2-BA.5 codon optimized sequence)

[0336] SEQ ID NO.10 (SF-3-BA.5 codon optimized sequence)

[0337] SEQ ID NO.11 (SF-4-BA.5 codon optimized sequence)

[0338] SEQ ID NO.12 (SF-5-BA.5 codon optimized sequence)

[0339] SEQ ID NO.13 (SF-6-XBB-1 codon-optimized sequence)

[0340] SEQ ID NO.14 (SF-7-XBB-2 codon optimized sequence)

[0341] SEQ ID NO.15 (SF-8-BA.2.75-1 codon optimized sequence)

[0342] SEQ ID NO.16 (SF-9-BA.2.75-2 codon optimized sequence)

[0343] SEQ ID NO.17 (SF-10-BQ.1-01 codon-optimized sequence)

[0344] SEQ ID NO.18 (SF-11-BQ.1-02 codon-optimized sequence)

[0345] SEQ ID NO.19 (SF-12-BF.7-01 codon-optimized sequence)

[0346] SEQ ID NO.20 (SF-13-BF.7-02 codon optimized sequence)

[0347] SEQ ID NO.21 (SF-14-Ch.1.1-01 codon-optimized sequence)

[0348] SEQ ID NO.22 (SF-15-XBB.1.5 codon optimized sequence)

[0349] SEQ ID NO.23 (SF-16-XBB.1.16 codon optimized sequence)

[0350] SEQ ID NO.24 (SF-17-BA.5 codon-optimized sequence)

[0351] SEQ ID NO.25 (SF-18-BA.5 codon optimized sequence)

[0352] SEQ ID NO.26 (SF-19-BA.5 codon-optimized sequence)

[0353] SEQ IND NO:27 luciferase RNA sequence

[0354] Note: T and U in the above sequence are interchangeable and can be replaced in whole or in part with modified bases, such as 1-methylpseudouridine or pseudouridine.

[0355] SEQ ID NO:28

[0356] SEQ ID NO:29

[0357] SEQ ID NO:30

[0358] SEQ ID NO:31

[0359] SEQ ID NO:32

Claims

1. A lipid nanoparticle composition for encapsulating nucleic acids, wherein the empty loading rate of the lipid nanoparticles is not more than 10%, preferably not more than 9%, and more preferably not more than 8.5%, wherein the empty loading rate refers to the ratio of the number of empty lipid nanoparticles that do not contain nucleic acids in the composition to the total number of lipid nanoparticles.

2. The composition of claim 1, wherein the average particle size of the lipid nanoparticles is 50 nm to 150 nm, preferably 70 nm to 120 nm, and more preferably 90 nm to 110 nm.

3. The composition of claim 1, wherein the encapsulation efficiency of the lipid nanoparticles is above 80%, preferably above 85%, and more preferably above 90%.

4. The composition of any one of claims 1 to 3, wherein the lipid nanoparticles comprise: (1) nucleic acids, and (2) A lipid component, which comprises an ionizable cationic lipid, a helper lipid, a structural lipid and a surfactant.

5. The composition of claim 4, wherein the lipid component comprises 20-60 mol% ionizable cationic lipids, 25-55 mol% structural lipids, 2-25 mol% auxiliary lipids and 0.5-15 mol% surfactant, based on the total molar content of the lipid component of 100%.

6. A composition as described in claim 4 or 5, wherein the cationic lipid is selected from SM-102, ALC-0315, Dlin-MC3-DMA, DODMA, C12-200 and DlinDMA, and / or the structural lipid is selected from cholesterol or cholesterol derivatives, and / or the auxiliary lipid is selected from DSPC, DOPE, DOPC, DOPG and DOPS, and / or the surfactant is selected from mPEG-DMG-2K, ALC-0159, PEG-DSPE, DTDA-PEG2000 and TPGS.

7. The composition of claim 4 or 5, wherein the lipid nanoparticles have an N:P ratio of about 2:1 to about 30:1, preferably about 2:1 to about 15:1, more preferably about 2:1 to about 10:1, and even more preferably about 3:1 to about 6:

1.

8. The composition of claim 4, wherein the weight ratio of ionizable cationic lipid to nucleic acid is from about 5:1 to about 100:1, preferably from about 5:1 to about 50:1, more preferably from about 5:1 to about 30:1, and even more preferably from about 10:1 to about 20:

1.

9. The composition of claim 4, wherein the lipid nanoparticle composition further comprises a finished product buffer comprising a buffering agent and / or a cryoprotectant.

10. The composition of claim 9, wherein the buffer is selected from acetate, formate, carbonate, phosphate, borate, succinate, gluconate, lactate, citrate, glycine, leucine, barbituric acid, phthalic acid, tromethamine (Tris), triethylamine, ammonium salts and combinations thereof, and the pH of the buffer is 7-8, and / or The cryoprotectant is selected from the group consisting of sugars, polyols, polymers, surfactants, amino acids and salts, wherein the sugar is selected from the group consisting of lactose, sucrose, trehalose and galactose.

11. The composition of claim 9, wherein the finished buffer comprises tromethamine, sodium acetate and sucrose, and the pH value of the buffer is 7-8.

12. A composition as claimed in claim 1, wherein the nucleic acid is selected from mRNA, the mRNA comprising a nucleotide sequence having at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99% or 100% identity with the nucleotide sequence of any one of SEQ ID NO: 1 to SEQ ID NO: 6, or the coronavirus antigen encoded by it comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99% or 100% identity with the amino acid sequence of SEQ ID NO: 7, or it comprises a nucleotide sequence having at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99% or 100% identity with the nucleotide sequence of any one of SEQ ID NO: 8 to 26, preferably, the mRNA comprises the nucleotide sequence of SEQ ID NO: 1, more preferably, the mRNA is the nucleotide sequence of SEQ ID NO:

1.

13. The composition of claim 1, comprising lipid nanoparticles encapsulating nucleic acid, tromethamine, sodium acetate and sucrose, wherein The pH of the composition is 7.0-8.0; The nucleic acid is mRNA, and its concentration is 100 μg / ml; and The lipid components of the lipid nanoparticles include 50 mol% SM-102, 10 mol% DSPC, 38.5 mol% cholesterol and 1.5 mol% mPEG-DMG-2K.

14. A method for preparing a lipid nanoparticle composition according to any one of claims 1 to 13, wherein include: Precursor lipid nanoparticles are prepared to obtain a buffer system containing the precursor lipid nanoparticles, and the buffer system containing the precursor lipid nanoparticles is replaced with a neutral buffer system to obtain a finished lipid nanoparticle composition, wherein, through the buffer system replacement, the content of the organic solvent in the buffer system containing the precursor lipid nanoparticles is reduced to less than or equal to 5% (w / w), preferably less than 3% (w / w) when the pH value of the system is lower than the pKa of the lipid nanoparticles by more than 0.5 units.

15. The preparation method according to claim 14, wherein the buffer system replacement comprises a two-stage buffer system replacement process, preferably, the two-stage buffer system replacement process comprises replacement with an acidic buffer or a neutral buffer in the first stage, and replacement with a neutral buffer in the second stage.

16. The preparation method according to claim 15, wherein the replacement process is selected from one or more of tangential flow filtration, membrane dialysis, column dialysis, and dilution.

17. The preparation method according to claim 15, in: At the end of the first stage, the pH value of the buffer system containing the precursor lipid nanoparticles is lower than the pKa of the lipid nanoparticles by more than 0.5 units, and the content of the organic solvent is reduced to less than or equal to 5% (w / w), preferably less than 3% (w / w); and / or At the end of the second stage, the pH value of the buffer system containing the finished lipid nanoparticles is higher than the pKa of the lipid nanoparticles by more than 0.5 units, and / or the organic solvent content in the buffer system containing the finished lipid nanoparticles is reduced to less than 1% (w / w), preferably less than 0.1% (w / w).

18. The preparation method of claim 15, wherein the pH of the acidic buffer is less than the pKa of the lipid nanoparticles, and the buffer comprises a buffer selected from the group consisting of acetate, formate, carbonate, phosphate, borate, succinate, gluconate, lactate, citric acid, glycine, leucine, barbituric acid, phthalic acid, tromethamine (Tris), triethylamine, ammonium salts, and combinations thereof, and optionally an osmotic pressure regulator selected from the group consisting of sodium chloride and potassium chloride, preferably, the buffer comprises citric acid and sodium chloride.

19. The preparation method of claim 15, wherein the pH of the neutral buffer is greater than the pKa of the lipid nanoparticles, and the buffer comprises a buffer selected from the group consisting of acetate, formate, carbonate, phosphate, borate, succinate, gluconate, lactate, citric acid, glycine, leucine, barbituric acid, phthalic acid, tromethamine (Tris), triethylamine, ammonium salts, and combinations thereof, and optionally a cryoprotectant selected from the group consisting of sugars, polyols, polymers, surfactants, amino acids, and salts, preferably, the buffer comprises tromethamine, sodium acetate, and sucrose.

20. The preparation method according to any one of claims 14 to 19, wherein the pKa of the lipid nanoparticles is 6.0-7.

0.

21. The preparation method of claim 14, wherein the precursor lipid nanoparticles are prepared as follows: The lipid components including ionizable cationic lipids, auxiliary lipids, structural lipids and surfactants are dissolved in an organic solvent to form a lipid phase; the nucleic acid is dissolved in an acidic buffer to form a and mixing the lipid phase and the aqueous phase to form lipid nanoparticles containing the lipid-encapsulated nucleic acid, or The lipid components including ionizable cationic lipids, auxiliary lipids, structural lipids and surfactants are dissolved in an organic solvent to form a lipid phase, and the lipid phase and an acidic buffer are mixed to form blank lipid nanoparticles; nucleic acids are dissolved in an acidic buffer to form an aqueous phase; and the blank lipid nanoparticles are mixed with the aqueous phase containing nucleic acids to allow the lipids to encapsulate the nucleic acids to form precursor lipid nanoparticles.

22. The method for preparing a lipid nanoparticle composition encapsulating nucleic acid according to any one of claims 1 to 13, wherein The following steps are involved: (1) dissolving the lipid component in an organic solvent to form an organic phase; (2) dissolving the nucleic acid in an acidic buffer to form an aqueous phase; (3) mixing the organic phase and the aqueous phase, encapsulating the nucleic acid with lipids to form precursor lipid nanoparticles; and (4) replacing the organic solvent-acidic buffer system containing the precursor lipid nanoparticles obtained in step (3) with a neutral buffer system in two stages to obtain a finished lipid nanoparticle composition, wherein the first stage uses an acidic buffer or a neutral buffer for replacement, and the second stage uses a neutral buffer for replacement.

23. The preparation method of claim 22, wherein in step (4), at the end of the first stage, the pH of the buffer system containing the precursor lipid nanoparticles is lower than the pKa of the lipid nanoparticles by more than 0.5 units, and / or the organic solvent content in the buffer system containing the precursor lipid nanoparticles is reduced to less than or equal to 5% (w / w), preferably less than 3% (w / w).

24. The preparation method of claim 22, wherein in step (4), at the end of the second stage, the pH value of the buffer system containing the finished lipid nanoparticles is higher than the pKa of the lipid nanoparticles by more than 0.5 units, and / or the organic solvent content in the buffer system containing the finished lipid nanoparticles is reduced to less than 1% (w / w), preferably less than 0.1% (w / w).

25. The preparation method as claimed in claim 22, wherein the method optionally comprises step (5) concentration, dilution, sterile filtration, aseptic filling or a combination thereof.

26. The preparation method as claimed in claim 22, wherein the organic solvent in step (1) is selected from C1-C4 low-carbon alcohols, preferably ethanol.

27. The preparation method according to claim 22, wherein the total concentration of lipid components in the organic phase in step (1) is 10-15 mg / ml.

28. The preparation method as claimed in claim 22, wherein the nucleic acid concentration in the aqueous phase in step (2) is 0.01-1 mg / ml, preferably 0.05-0.5 mg / ml, and more preferably 0.1-0.2 mg / ml.

29. The preparation method as claimed in claim 22, wherein the acidic buffer described in step (2) or step (4) comprises a buffer selected from the group consisting of acetate, formate, carbonate, phosphate, borate, succinate, gluconate, lactate, citrate, glycine, leucine, barbituric acid, phthalic acid, tromethamine (Tris), triethylamine, ammonium salts and combinations thereof, and the pH value of the acidic buffer is less than the pKa of the lipid nanoparticles.

30. The preparation method as claimed in claim 29, wherein the pKa of the lipid nanoparticles is 6.0-7.0, and the pH value of the acidic buffer described in step (2) or step (4) is 3.0-5.0, preferably 4.0-5.

0.

31. The preparation method as claimed in claim 22, wherein the acidic buffer described in step (2) or step (4) further comprises an osmotic pressure regulator, and the osmotic pressure regulator is selected from sodium chloride and potassium chloride.

32. The preparation method as claimed in claim 31, wherein the acidic buffer described in step (2) or step (4) comprises citric acid and sodium chloride, preferably, comprises 10-20 mM citric acid and 120-140 mM sodium chloride.

33. The preparation method as claimed in claim 22, wherein the volume ratio of the organic phase and the aqueous phase mixed in step (3) is 1:2-1:9, preferably 1:2-1:5, and more preferably 1:

3.

34. The preparation method as claimed in claim 22, wherein the replacement process in step (4) is selected from one or more of tangential flow filtration, membrane dialysis, column dialysis, and dilution.

35. The preparation method as claimed in claim 22, wherein the two-stage replacement process in step (4) can be repeated multiple times.

36. The preparation method as claimed in claim 22, wherein the neutral buffer described in step (4) comprises a buffer selected from the following: acetate, formate, carbonate, phosphate, borate, succinate, gluconate, lactate, citrate, glycine, leucine, barbituric acid, phthalic acid, tromethamine (Tris), triethylamine, ammonium salts and combinations thereof, and the pH value of the neutral buffer is greater than the pKa of the lipid nanoparticles.

37. The preparation method of claim 36, wherein the pKa of the lipid nanoparticles is 6.0-7.0, and the pH value of the neutral buffer described in step (4) is 7.0-8.

0.

38. The preparation method as claimed in claim 36, wherein the neutral buffer described in step (4) further comprises a cryoprotectant selected from the group consisting of sugars, polyols, polymers, surfactants, amino acids and salts, wherein the sugar is selected from the group consisting of lactose, sucrose, trehalose and galactose.

Citation Information

Patent Citations

  • Lipid nanoparticles for enhancing immune effect of nucleic acid vaccines and preparation method of lipid nanoparticles

    CN110974954A

  • Lipid nanoparticle based on nitrogen heterocyclic cholesterol derivative and application of lipid nanoparticle

    CN115487168A

  • Immunogenic composition against influenza

    US20220362372A1

  • CN202111445859A